{"sentences":[{"sentenceIdx":0,"originalSentence":"TEP technique may carry a higher risk of conversion to another hernia repair method (either TAPP technique or open surgery) when compared to TAPP (2.5% versus 0.7%; OR 0.28, 95% CI 0.09 to 0.84, P = 0.02, I2 = 0%; 13 studies, 1178 participants; low certainty of evidence).","elementMap":{"45c5c3c0208f4b4bafba95662388d3c6":{"id":"45c5c3c0208f4b4bafba95662388d3c6","parseTree":"(ROOT (S (NP (NNP TEP) (NN technique)) (VP (MD may) (VP (VB carry) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (NN conversion)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NNP TAPP))) (PRN (-LRB- -LRB-) (NP (NP (CD 2.5) (NN %)) (PP (IN versus) (NP (NP (CD 0.7) (NN %)) (: ;) (NP (NNP OR) (NNP 0.28) (NNP P))))) (-RRB- -RRB-))))))) (. .)))","sentenceIdx":0,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"3270ffd8c1d34a07bd5f242d61229469","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"f6f5a59ed6154f5698bc6d2999f645ea","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"fd4bb033dd2544b0b6922070897da2e7","relation":"IDENTIFYING_DEFINITION"},{"targetID":"74f726f0cb5d405ea7081760949572ab","relation":"ELABORATION"},{"targetID":"799c15a5d3d44970890787f573b447b1","relation":"ELABORATION"}],"text":"TEP technique may carry a higher risk of conversion when compared to TAPP -LRB- 2.5 % versus 0.7 % ; OR 0.28 P -RRB- ."},"3270ffd8c1d34a07bd5f242d61229469":{"id":"3270ffd8c1d34a07bd5f242d61229469","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT another) (NN hernia) (NN repair) (NN method)) (PRN (-LRB- -LRB-) (NP (RB either) (JJ TAPP) (NN technique)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":0,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"f6f5a59ed6154f5698bc6d2999f645ea","relation":"DISJUNCTION"}],"text":"This was to another hernia repair method -LRB- either TAPP technique -RRB- ."},"f6f5a59ed6154f5698bc6d2999f645ea":{"id":"f6f5a59ed6154f5698bc6d2999f645ea","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT another) (NN hernia) (NN repair) (NN method)) (PRN (-LRB- -LRB-) (NP (JJ open) (NN surgery)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":0,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"3270ffd8c1d34a07bd5f242d61229469","relation":"DISJUNCTION"}],"text":"This was to another hernia repair method -LRB- open surgery -RRB- ."},"fd4bb033dd2544b0b6922070897da2e7":{"id":"fd4bb033dd2544b0b6922070897da2e7","parseTree":"(ROOT (S (S (VP (SYM =) (NP (CD 0.02)))) (NP (NNP OR) (NNP 0.28)) (VP (VBP P)) (. .)))","sentenceIdx":0,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"= 0.02 OR 0.28 P ."},"74f726f0cb5d405ea7081760949572ab":{"id":"74f726f0cb5d405ea7081760949572ab","parseTree":"(ROOT (NP (NP (NP (NNP OR) (CD 0.28)) (SBAR (S (NP (NNP P) (NNP =) (NNP 0.02)) (VP (VBD was) (VP (VBN I2) (S (VP (SYM =) (NP (CD 0) (NN %))))))))) (: ;) (NP (NP (CD 13) (NNS studies)) (, ,) (NP (CD 1178) (NNS participants))) (: ;) (NP (NP (JJ low) (NN certainty)) (PP (IN of) (NP (NN evidence)))) (. .)))","sentenceIdx":0,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"OR 0.28 P = 0.02 was I2 = 0 % ; 13 studies , 1178 participants ; low certainty of evidence ."},"799c15a5d3d44970890787f573b447b1":{"id":"799c15a5d3d44970890787f573b447b1","parseTree":"(ROOT (S (NP (NP (CD 2.5) (NN %)) (PP (IN versus) (NP (NP (CD 0.7) (NN %)) (: ;) (NP (NNP OR) (CD 0.28))))) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NNP CI) (CD 0.09)) (PP (TO to) (NP (CD 0.84))))) (. .)))","sentenceIdx":0,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"2.5 % versus 0.7 % ; OR 0.28 was 95 % CI 0.09 to 0.84 ."}}},{"sentenceIdx":1,"originalSentence":"An inguinal hernia occurs when part of the intestine protrudes through the abdominal muscles. ","elementMap":{"8f5a75c268834a19b9dee3c41faae1b4":{"id":"8f5a75c268834a19b9dee3c41faae1b4","parseTree":"(ROOT (S (NP (DT An) (JJ inguinal) (NN hernia)) (VP (VBZ occurs)) (. .)))","sentenceIdx":1,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"35d65d29bcfb49df9e98aeeae5872076","relation":"BACKGROUND"}],"text":"An inguinal hernia occurs ."},"35d65d29bcfb49df9e98aeeae5872076":{"id":"35d65d29bcfb49df9e98aeeae5872076","parseTree":"(ROOT (S (NP (NP (NN Part)) (PP (IN of) (NP (DT the) (NN intestine)))) (VP (VBZ protrudes) (PP (IN through) (NP (DT the) (JJ abdominal) (NNS muscles)))) (. .)))","sentenceIdx":1,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Part of the intestine protrudes through the abdominal muscles ."}}},{"sentenceIdx":2,"originalSentence":"There may be little to no difference between TAPP and TEP laparoscopic techniques for serious adverse events and hernia recurrence.","elementMap":{"f9a54196645941c29e546b5dcf6a4cea":{"id":"f9a54196645941c29e546b5dcf6a4cea","parseTree":"(ROOT (S (NP (EX There)) (VP (MD may) (VP (VB be) (ADJP (JJ little) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (NNP TAPP) (CC and) (NNP TEP) (JJ laparoscopic) (NNS techniques)))))) (PP (IN for) (NP (JJ serious) (JJ adverse) (NNS events))))) (. .)))","sentenceIdx":2,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"3a077e25de8945bc9ef6868d34a1da6f","relation":"LIST"}],"text":"There may be little to no difference between TAPP and TEP laparoscopic techniques for serious adverse events ."},"3a077e25de8945bc9ef6868d34a1da6f":{"id":"3a077e25de8945bc9ef6868d34a1da6f","parseTree":"(ROOT (S (NP (EX There)) (VP (MD may) (VP (VB be) (ADJP (JJ little) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (NNP TAPP) (CC and) (NNP TEP) (JJ laparoscopic) (NNS techniques)))))) (PP (IN for) (NP (NN hernia) (NN recurrence))))) (. .)))","sentenceIdx":2,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"f9a54196645941c29e546b5dcf6a4cea","relation":"LIST"}],"text":"There may be little to no difference between TAPP and TEP laparoscopic techniques for hernia recurrence ."}}},{"sentenceIdx":3,"originalSentence":"TEP technique may carry a higher risk of conversion to another hernia repair method (either TAPP technique or open surgery) when compared to TAPP.","elementMap":{"63163b145d7f4bf98b2c294e0a9f41e3":{"id":"63163b145d7f4bf98b2c294e0a9f41e3","parseTree":"(ROOT (S (NP (NNP TEP) (NN technique)) (VP (MD may) (VP (VB carry) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (NN conversion)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NNP TAPP)))))))) (. .)))","sentenceIdx":3,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"795ec97da68c4ed5a8e2327dfb6cfa49","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"8153b042bbab4feab306307509532575","relation":"UNKNOWN_SUBORDINATION"}],"text":"TEP technique may carry a higher risk of conversion when compared to TAPP ."},"795ec97da68c4ed5a8e2327dfb6cfa49":{"id":"795ec97da68c4ed5a8e2327dfb6cfa49","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT another) (NN hernia) (NN repair) (NN method)) (PRN (-LRB- -LRB-) (NP (RB either) (JJ TAPP) (NN technique)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":3,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"8153b042bbab4feab306307509532575","relation":"DISJUNCTION"}],"text":"This was to another hernia repair method -LRB- either TAPP technique -RRB- ."},"8153b042bbab4feab306307509532575":{"id":"8153b042bbab4feab306307509532575","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT another) (NN hernia) (NN repair) (NN method)) (PRN (-LRB- -LRB-) (NP (JJ open) (NN surgery)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":3,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"795ec97da68c4ed5a8e2327dfb6cfa49","relation":"DISJUNCTION"}],"text":"This was to another hernia repair method -LRB- open surgery -RRB- ."}}},{"sentenceIdx":4,"originalSentence":"CBT may result in a small‐to‐moderate reduction of anxiety post‐treatment (SMD ‐0.51, 95% CI ‐0.66 to ‐0.36, low‐certainty evidence). ","elementMap":{"24c4278662db4af192639718968c81f9":{"id":"24c4278662db4af192639718968c81f9","parseTree":"(ROOT (S (NP (NNP CBT)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ small‐to‐moderate) (NN reduction)) (PP (IN of) (NP (NP (NN anxiety) (NN post‐treatment)) (PRN (-LRB- -LRB-) (NP (NP (NNP SMD) (CD 0.51)) (NP (JJ low‐certainty) (NN evidence))) (-RRB- -RRB-)))))))) (. .)))","sentenceIdx":4,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"5d34b02402ce428b8acd4acc23522a9a","relation":"ELABORATION"}],"text":"CBT may result in a small‐to‐moderate reduction of anxiety post‐treatment -LRB- SMD 0.51 low‐certainty evidence -RRB- ."},"5d34b02402ce428b8acd4acc23522a9a":{"id":"5d34b02402ce428b8acd4acc23522a9a","parseTree":"(ROOT (S (NP (NNP SMD) (NNP 0.51)) (VP (VBZ is) (NP (NP (ADJP (CD 95) (NN %)) (NNP CI) (NNP 0.66)) (PP (TO to) (NP (CD 0.36))))) (. .)))","sentenceIdx":4,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"SMD 0.51 is 95 % CI 0.66 to 0.36 ."}}},{"sentenceIdx":5,"originalSentence":"However, compared to this benefit with CBT immediately after treatment, at three to six months post‐treatment, there was little to no difference between CBT and minimal management (SMD ‐0.29, 95% CI ‐0.59 to 0.01, low‐certainty evidence).","elementMap":{"a6cdb0060f3b48f5bd5e36eee90f7fb1":{"id":"a6cdb0060f3b48f5bd5e36eee90f7fb1","parseTree":"(ROOT (S (NP (EX There)) (VP (VBD was) (ADJP (JJ little) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (NNP CBT)))))) (PRN (-LRB- -LRB-) (NP (QP (CD SMD) (CD 0.29)) (NN low‐certainty) (NN evidence)) (-RRB- -RRB-))) (. .)))","sentenceIdx":5,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (ADVP (RB however))) (. .)))","phrase":"(ROOT (FRAG (ADVP (RB however)) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was however .","phraseText":"however ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN at) (NP (QP (CD three) (TO to) (CD six)) (NNS months)))) (. .)))","phrase":"(ROOT (NP (NP (QP (IN at) (CD three))) (PP (TO to) (NP (CD six) (NNS months))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was at three to six months .","phraseText":"at three to six months ."}],"linkedContexts":[{"targetID":"a6275ed5b3724379ad0a9b0b03888b20","relation":"LIST"},{"targetID":"18a76602da6247a89459ee40c0428bef","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"407df69f57b54a018972eaa647d5daaa","relation":"ELABORATION"}],"text":"There was little to no difference between CBT -LRB- SMD 0.29 low‐certainty evidence -RRB- ."},"a6275ed5b3724379ad0a9b0b03888b20":{"id":"a6275ed5b3724379ad0a9b0b03888b20","parseTree":"(ROOT (S (NP (EX There)) (VP (VBD was) (ADJP (JJ little) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (JJ minimal) (NN management)))))) (PRN (-LRB- -LRB-) (NP (QP (CD SMD) (CD 0.29)) (NN low‐certainty) (NN evidence)) (-RRB- -RRB-))) (. .)))","sentenceIdx":5,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (ADVP (RB however))) (. .)))","phrase":"(ROOT (FRAG (ADVP (RB however)) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was however .","phraseText":"however ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN at) (NP (QP (CD three) (TO to) (CD six)) (NNS months)))) (. .)))","phrase":"(ROOT (NP (NP (QP (IN at) (CD three))) (PP (TO to) (NP (CD six) (NNS months))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was at three to six months .","phraseText":"at three to six months ."}],"linkedContexts":[{"targetID":"a6cdb0060f3b48f5bd5e36eee90f7fb1","relation":"LIST"},{"targetID":"18a76602da6247a89459ee40c0428bef","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"407df69f57b54a018972eaa647d5daaa","relation":"ELABORATION"}],"text":"There was little to no difference between minimal management -LRB- SMD 0.29 low‐certainty evidence -RRB- ."},"18a76602da6247a89459ee40c0428bef":{"id":"18a76602da6247a89459ee40c0428bef","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (VBN compared) (PP (TO to) (NP (NP (DT this) (NN benefit)) (PP (IN with) (NP (NNP CBT))))))) (. .)))","sentenceIdx":5,"contextLayer":1,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (ADVP (RB immediately)) (PP (IN after) (NP (NN treatment) (NN post‐treatment)))) (. .)))","phrase":"(ROOT (FRAG (PP (ADVP (RB immediately)) (IN after) (NP (NN treatment) (NN post‐treatment))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was immediately after treatment post‐treatment .","phraseText":"immediately after treatment post‐treatment ."}],"linkedContexts":[],"text":"This was compared to this benefit with CBT ."},"407df69f57b54a018972eaa647d5daaa":{"id":"407df69f57b54a018972eaa647d5daaa","parseTree":"(ROOT (S (NP (NNP SMD) (CD 0.29)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NNP CI) (CD 0.59)) (PP (TO to) (NP (CD 0.01))))) (. .)))","sentenceIdx":5,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"SMD 0.29 was 95 % CI 0.59 to 0.01 ."}}},{"sentenceIdx":6,"originalSentence":"CBT may result in a reduction of comorbid depression symptoms post‐treatment (SMD ‐0.57, 95% CI ‐0.74 to ‐0.40, low‐certainty evidence).","elementMap":{"68399c4abf0144248c256e08f20b51c6":{"id":"68399c4abf0144248c256e08f20b51c6","parseTree":"(ROOT (S (NP (NNP CBT)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (ADJP (JJ comorbid)) (NN depression) (NNS symptoms) (NN post‐treatment)) (PRN (-LRB- -LRB-) (NP (NP (NNP SMD) (CD 0.57)) (NP (JJ low‐certainty) (NN evidence))) (-RRB- -RRB-)))))))) (. .)))","sentenceIdx":6,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"991f6b117f9447a7b85d21ba2d87bcab","relation":"ELABORATION"}],"text":"CBT may result in a reduction of comorbid depression symptoms post‐treatment -LRB- SMD 0.57 low‐certainty evidence -RRB- ."},"991f6b117f9447a7b85d21ba2d87bcab":{"id":"991f6b117f9447a7b85d21ba2d87bcab","parseTree":"(ROOT (S (NP (NNP SMD) (NNP 0.57)) (VP (VBZ is) (NP (CD 95) (NN %))) (. .)))","sentenceIdx":6,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"74f4b89267e0407ebe1b021ae40af624","relation":"IDENTIFYING_DEFINITION"}],"text":"SMD 0.57 is 95 % ."},"74f4b89267e0407ebe1b021ae40af624":{"id":"74f4b89267e0407ebe1b021ae40af624","parseTree":"(ROOT (S (VP (VB CI) (NP (QP (CD 0.74) (TO to) (CD 0.40) (CD 95)) (NN %))) (. .)))","sentenceIdx":6,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"CI 0.74 to 0.40 95 % ."}}},{"sentenceIdx":7,"originalSentence":"There is not enough evidence to determine whether CBT is more effective than alternative psychological therapies for anxiety in older adults.","elementMap":{"50f08d5b3fce4c618d2a132b7efd3f69":{"id":"50f08d5b3fce4c618d2a132b7efd3f69","parseTree":"(ROOT (S (NP (EX There)) (VP (VBZ is) (RB not) (NP (JJ enough) (NN evidence) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NNP CBT)) (VP (VBZ is) (ADJP (RBR more) (JJ effective) (PP (IN than) (NP (NP (JJ alternative) (JJ psychological) (NNS therapies)) (PP (IN for) (NP (NP (NN anxiety)) (PP (IN in) (NP (JJR older) (NNS adults)))))))))))))))) (. .)))","sentenceIdx":7,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"There is not enough evidence to determine whether CBT is more effective than alternative psychological therapies for anxiety in older adults ."}}},{"sentenceIdx":8,"originalSentence":"To assess the effects of Cognitive Behavioural Therapy (CT, BT, CBT and third‐wave CBT interventions) on severity of anxiety symptoms compared with minimal management (not providing therapy) for anxiety and related disorders in older adults, aged 55 years or over. ","elementMap":{"d9200f2eab1747cc9e1f38a1085d9ce3":{"id":"d9200f2eab1747cc9e1f38a1085d9ce3","parseTree":"(ROOT (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Cognitive) (NNP Behavioural) (NNP Therapy)) (PRN (-LRB- -LRB-) (NP (NP (NNP CT)) (, ,) (NP (NNP BT)) (, ,) (NP (NNP CBT)) (CC and) (NP (JJ third‐wave) (NNP CBT) (NNS interventions))) (-RRB- -RRB-))))))) (. .)))","sentenceIdx":8,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (VP (VBN compared) (PP (IN with) (NP (JJ minimal) (NN management))) (PRN (-LRB- -LRB-) (S (VP (RB not) (VBG providing) (NP (NN therapy)))) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NN anxiety) (CC and) (VBN related) (NNS disorders)) (UCP (PP (IN in) (NP (JJR older) (NNS adults))) (, ,) (VP (VBN aged) (NP-TMP (CD 55) (NNS years))) (CC or) (PP (IN over))))))) (. .)))","phrase":"(ROOT (S (PP (VBN compared) (PP (IN with) (NP (NP (NP (NP (JJ minimal) (NN management)) (PRN (-LRB- -LRB-) (NP (RB not) (JJ providing) (NN therapy)) (-RRB- -RRB-))) (PP (IN for) (NP (NN anxiety)))) (CC and) (NP (NP (VBN related) (NNS disorders)) (PP (IN in) (NP (JJR older) (NNS adults))))))) (, ,) (VP (VB aged) (ADVP (NP (CD 55) (NNS years)) (CC or) (ADVP (RB over)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was compared with minimal management -LRB- not providing therapy -RRB- for anxiety and related disorders in older adults , aged 55 years or over .","phraseText":"compared with minimal management -LRB- not providing therapy -RRB- for anxiety and related disorders in older adults , aged 55 years or over ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN on) (NP (NP (NN severity)) (PP (IN of) (NP (NN anxiety) (NNS symptoms)))))) (. .)))","phrase":"(ROOT (FRAG (PP (IN on) (NP (NP (NN severity)) (PP (IN of) (NP (NN anxiety) (NNS symptoms))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was on severity of anxiety symptoms .","phraseText":"on severity of anxiety symptoms ."}],"linkedContexts":[],"text":"To assess the effects of Cognitive Behavioural Therapy -LRB- CT , BT , CBT and third‐wave CBT interventions -RRB- ."}}},{"sentenceIdx":9,"originalSentence":"Percutaneous and surgical interventions combined with albendazole can be used to treat uncomplicated hepatic cystic echinococcosis; however, there is a scarcity of randomised evidence directly comparing these interventions. ","elementMap":{"10d6471fcb8742d29e4be4649021bef7":{"id":"10d6471fcb8742d29e4be4649021bef7","parseTree":"(ROOT (S (NP (NNS Percutaneous)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ uncomplicated) (JJ hepatic) (JJ cystic) (NNS echinococcosis)))))))) (. .)))","sentenceIdx":9,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"078b7f2798a645ec93dd6f71e746606f","relation":"LIST"},{"targetID":"ddb3ffcfe85a4d46b6361b3a58ea45e8","relation":"CONTRAST"}],"text":"Percutaneous can be used to treat uncomplicated hepatic cystic echinococcosis ."},"078b7f2798a645ec93dd6f71e746606f":{"id":"078b7f2798a645ec93dd6f71e746606f","parseTree":"(ROOT (S (NP (NP (NNP Surgical) (NNS interventions)) (PP (VBN combined) (PP (IN with) (NP (NN albendazole))))) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ uncomplicated) (JJ hepatic) (JJ cystic) (NNS echinococcosis)))))))) (. .)))","sentenceIdx":9,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"10d6471fcb8742d29e4be4649021bef7","relation":"LIST"},{"targetID":"ddb3ffcfe85a4d46b6361b3a58ea45e8","relation":"CONTRAST"}],"text":"Surgical interventions combined with albendazole can be used to treat uncomplicated hepatic cystic echinococcosis ."},"ddb3ffcfe85a4d46b6361b3a58ea45e8":{"id":"ddb3ffcfe85a4d46b6361b3a58ea45e8","parseTree":"(ROOT (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT a) (NN scarcity)) (PP (IN of) (NP (JJ randomised) (NN evidence))))) (. .)))","sentenceIdx":9,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"2570a7e6970c4a03888c43a7d8cb2b7b","relation":"IDENTIFYING_DEFINITION"},{"targetID":"10d6471fcb8742d29e4be4649021bef7","relation":"CONTRAST"},{"targetID":"078b7f2798a645ec93dd6f71e746606f","relation":"CONTRAST"}],"text":"There is a scarcity of randomised evidence ."},"2570a7e6970c4a03888c43a7d8cb2b7b":{"id":"2570a7e6970c4a03888c43a7d8cb2b7b","parseTree":"(ROOT (S (NP (JJ Randomised) (NN evidence)) (VP (VBZ is) (VP (VBG comparing) (NP (DT these) (NNS interventions)))) (. .)))","sentenceIdx":9,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Randomised evidence is comparing these interventions ."}}},{"sentenceIdx":10,"originalSentence":"To evaluate the benefits and harms of preoperative statin therapy in adults undergoing cardiac surgery compared to standard of care or placebo. ","elementMap":{"60101f49a37948b79716331a5b64c7c7":{"id":"60101f49a37948b79716331a5b64c7c7","parseTree":"(ROOT (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NNS benefits) (CC and) (NNS harms)) (PP (IN of) (NP (JJ preoperative) (NN statin) (NN therapy)))))) (. .)))","sentenceIdx":10,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"aab530ec02204f8aba051ac8563fafce","relation":"UNKNOWN_SUBORDINATION"}],"text":"To evaluate the benefits and harms of preoperative statin therapy ."},"aab530ec02204f8aba051ac8563fafce":{"id":"aab530ec02204f8aba051ac8563fafce","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NNS adults)))) (. .)))","sentenceIdx":10,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"ad18e4d7e6904232a9588ea0c396df49","relation":"IDENTIFYING_DEFINITION"}],"text":"This was in adults ."},"ad18e4d7e6904232a9588ea0c396df49":{"id":"ad18e4d7e6904232a9588ea0c396df49","parseTree":"(ROOT (S (NP (NNS Adults)) (VP (VBD were) (VP (VBG undergoing) (NP (JJ cardiac) (NN surgery)))) (. .)))","sentenceIdx":10,"contextLayer":2,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (VBN compared) (PP (TO to) (NP (NP (NN standard)) (PP (IN of) (NP (NN care) (CC or) (NN placebo))))))) (. .)))","phrase":"(ROOT (FRAG (PP (VBN compared) (PP (TO to) (NP (NP (NN standard)) (PP (IN of) (NP (NN care) (CC or) (NN placebo)))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was compared to standard of care or placebo .","phraseText":"compared to standard of care or placebo ."}],"linkedContexts":[],"text":"Adults were undergoing cardiac surgery ."}}},{"sentenceIdx":11,"originalSentence":"We included all randomised controlled trials (RCTs) comparing any statin treatment before cardiac surgery, for any given duration and dose, versus no preoperative statin therapy (standard of care) or placebo. ","elementMap":{"f312250d66f7421c9cff264d88208fd3":{"id":"f312250d66f7421c9cff264d88208fd3","parseTree":"(ROOT (S (NP (PRP We)) (VP (VBD included)) (. .)))","sentenceIdx":11,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"a56fe9c076d44b10bc4275a59c06bd18","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"a8b7252f5e624a409dfeb6a58202c3b1","relation":"UNKNOWN_SUBORDINATION"}],"text":"We included ."},"a56fe9c076d44b10bc4275a59c06bd18":{"id":"a56fe9c076d44b10bc4275a59c06bd18","parseTree":"(ROOT (S (NP (DT All)) (VP (VBD randomised) (NP (NP (VBN controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-)) (PP (IN versus) (NP (NP (DT no) (JJ preoperative) (NN statin) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NN standard)) (PP (IN of) (NP (NN care)))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":11,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"a8b7252f5e624a409dfeb6a58202c3b1","relation":"DISJUNCTION"},{"targetID":"11103a683d8e4d558b627d6ba3f49db3","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"b85b0488d1d04761885f8e3f82ad874f","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"e5f239a3a41f474089bcde3e4f21c3e4","relation":"IDENTIFYING_DEFINITION"}],"text":"All randomised controlled trials -LRB- RCTs -RRB- versus no preoperative statin therapy -LRB- standard of care -RRB- ."},"a8b7252f5e624a409dfeb6a58202c3b1":{"id":"a8b7252f5e624a409dfeb6a58202c3b1","parseTree":"(ROOT (S (NP (DT All)) (VP (VBD randomised) (NP (NP (VBN controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-)) (PP (IN versus) (NP (NN placebo))))) (. .)))","sentenceIdx":11,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"a56fe9c076d44b10bc4275a59c06bd18","relation":"DISJUNCTION"},{"targetID":"11103a683d8e4d558b627d6ba3f49db3","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"b85b0488d1d04761885f8e3f82ad874f","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"e5f239a3a41f474089bcde3e4f21c3e4","relation":"IDENTIFYING_DEFINITION"}],"text":"All randomised controlled trials -LRB- RCTs -RRB- versus placebo ."},"11103a683d8e4d558b627d6ba3f49db3":{"id":"11103a683d8e4d558b627d6ba3f49db3","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (DT any) (VBN given) (NN duration)))) (. .)))","sentenceIdx":11,"contextLayer":2,"simpleContexts":[],"linkedContexts":[{"targetID":"b85b0488d1d04761885f8e3f82ad874f","relation":"LIST"}],"text":"This was for any given duration ."},"b85b0488d1d04761885f8e3f82ad874f":{"id":"b85b0488d1d04761885f8e3f82ad874f","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (NN dose)))) (. .)))","sentenceIdx":11,"contextLayer":2,"simpleContexts":[],"linkedContexts":[{"targetID":"11103a683d8e4d558b627d6ba3f49db3","relation":"LIST"}],"text":"This was for dose ."},"e5f239a3a41f474089bcde3e4f21c3e4":{"id":"e5f239a3a41f474089bcde3e4f21c3e4","parseTree":"(ROOT (S (NP (NP (JJ Controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBG comparing) (NP (DT any) (NN statin) (NN treatment)))) (. .)))","sentenceIdx":11,"contextLayer":2,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN before) (NP (JJ cardiac) (NN surgery)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN before) (NP (JJ cardiac) (NN surgery))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was before cardiac surgery .","phraseText":"before cardiac surgery ."}],"linkedContexts":[],"text":"Controlled trials -LRB- RCTs -RRB- were comparing any statin treatment ."}}},{"sentenceIdx":12,"originalSentence":"We excluded trials without a registered trial protocol and trials without approval by an institutional ethics committee. ","elementMap":{"2082a03f696245f4959a9888d6141ee1":{"id":"2082a03f696245f4959a9888d6141ee1","parseTree":"(ROOT (S (NP (PRP We)) (VP (VBN excluded) (NP (NNS trials))) (. .)))","sentenceIdx":12,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN by) (NP (DT an) (JJ institutional) (NNS ethics) (NN committee)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN by) (NP (DT an) (JJ institutional) (NNS ethics) (NN committee))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was by an institutional ethics committee .","phraseText":"by an institutional ethics committee ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN without) (NP (NN approval)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN without) (NP (NN approval))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was without approval .","phraseText":"without approval ."}],"linkedContexts":[{"targetID":"690608ec1a1143d880987021ed532950","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"be6c876847594461aba7da5df499d054","relation":"UNKNOWN_SUBORDINATION"}],"text":"We excluded trials ."},"690608ec1a1143d880987021ed532950":{"id":"690608ec1a1143d880987021ed532950","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN without) (NP (DT a) (VBN registered) (NN trial) (NN protocol)))) (. .)))","sentenceIdx":12,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"be6c876847594461aba7da5df499d054","relation":"LIST"}],"text":"This was without a registered trial protocol ."},"be6c876847594461aba7da5df499d054":{"id":"be6c876847594461aba7da5df499d054","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN without) (NP (NNS trials)))) (. .)))","sentenceIdx":12,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"690608ec1a1143d880987021ed532950","relation":"LIST"}],"text":"This was without trials ."}}},{"sentenceIdx":13,"originalSentence":"Statins probably result in little to no difference in myocardial infarction (RR 0.88, 95% CI 0.73 to 1.06; I2 = 0%; 5 RCTs, 4645 participants; moderate‐certainty evidence), may result in little to no difference in atrial fibrillation (RR 0.87, 95% CI 0.72 to 1.05; I2 = 60%; 8 RCTs, 5592 participants; low‐certainty evidence), and may result in little to no difference in stroke (RR 1.47, 95% CI 0.90 to 2.40; I2 = 0%; 4 RCTs, 5143 participants; low‐certainty evidence).","elementMap":{"9ed92e28eaf64fbcaaec95e88904d0d7":{"id":"9ed92e28eaf64fbcaaec95e88904d0d7","parseTree":"(ROOT (S (NP (NNS Statins)) (ADVP (RB probably)) (VP (VBP result) (PP (IN in) (NP (RB little)))) (. .)))","sentenceIdx":13,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (JJ myocardial) (NN infarction)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.88)) (-RRB- -RRB-))))))) (. .)))","phrase":"(ROOT (FRAG (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (JJ myocardial) (NN infarction)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.88)) (-RRB- -RRB-)))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is to no difference in myocardial infarction -LRB- RR 0.88 -RRB- .","phraseText":"to no difference in myocardial infarction -LRB- RR 0.88 -RRB- ."}],"linkedContexts":[{"targetID":"2b22a73b2dd04cb89d524ad17bed0a66","relation":"ELABORATION"},{"targetID":"8e958e3acf06474faafa9e7d9de4cc69","relation":"ELABORATION"},{"targetID":"442c7be25e3f428ebcb27ebf9dd27010","relation":"ELABORATION"}],"text":"Statins probably result in little ."},"569e176ab1ad48ea8ff4f09644efbe9c":{"id":"569e176ab1ad48ea8ff4f09644efbe9c","parseTree":"(ROOT (S (NP (NNS Statins)) (ADVP (RB probably)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (RB little))))) (. .)))","sentenceIdx":13,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (JJ atrial) (NN fibrillation)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.87)) (-RRB- -RRB-))))))) (. .)))","phrase":"(ROOT (FRAG (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (JJ atrial) (NN fibrillation)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.87)) (-RRB- -RRB-)))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is to no difference in atrial fibrillation -LRB- RR 0.87 -RRB- .","phraseText":"to no difference in atrial fibrillation -LRB- RR 0.87 -RRB- ."}],"linkedContexts":[{"targetID":"2b22a73b2dd04cb89d524ad17bed0a66","relation":"ELABORATION"},{"targetID":"8e958e3acf06474faafa9e7d9de4cc69","relation":"ELABORATION"},{"targetID":"442c7be25e3f428ebcb27ebf9dd27010","relation":"ELABORATION"}],"text":"Statins probably may result in little ."},"c916ada587ae4036b1a0153b780f8d24":{"id":"c916ada587ae4036b1a0153b780f8d24","parseTree":"(ROOT (S (NP (NNS Statins)) (ADVP (RB probably)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (RB little))))) (. .)))","sentenceIdx":13,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (NN stroke)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.47)) (-RRB- -RRB-))))))) (. .)))","phrase":"(ROOT (FRAG (PP (TO to) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (NN stroke)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.47)) (-RRB- -RRB-)))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is to no difference in stroke -LRB- RR 1.47 -RRB- .","phraseText":"to no difference in stroke -LRB- RR 1.47 -RRB- ."}],"linkedContexts":[{"targetID":"2b22a73b2dd04cb89d524ad17bed0a66","relation":"ELABORATION"},{"targetID":"8e958e3acf06474faafa9e7d9de4cc69","relation":"ELABORATION"},{"targetID":"442c7be25e3f428ebcb27ebf9dd27010","relation":"ELABORATION"}],"text":"Statins probably may result in little ."},"2b22a73b2dd04cb89d524ad17bed0a66":{"id":"2b22a73b2dd04cb89d524ad17bed0a66","parseTree":"(ROOT (S (NP (NNP RR) (NNP 1.47)) (VP (VBZ is) (NP (CD 95) (NN %))) (. .)))","sentenceIdx":13,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"70cf9eda8e044dd38a97fe6f55bb0b38","relation":"IDENTIFYING_DEFINITION"},{"targetID":"76d9c28e3a7e44359918d312bde587bf","relation":"IDENTIFYING_DEFINITION"},{"targetID":"5c34ccefd92646e5bfe58984e0d071af","relation":"ELABORATION"}],"text":"RR 1.47 is 95 % ."},"70cf9eda8e044dd38a97fe6f55bb0b38":{"id":"70cf9eda8e044dd38a97fe6f55bb0b38","parseTree":"(ROOT (S (VP (VB CI) (NP (QP (CD 0.90) (CD 95)) (NN %))) (. .)))","sentenceIdx":13,"contextLayer":2,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (TO to) (NP (NP (CD 2.40)) (: ;) (NP (NNP I2)) (: ;) (NP (CD 4) (NNS RCTs)) (: ;) (NP (JJ low‐certainty) (NN evidence))))) (. .)))","phrase":"(ROOT (FRAG (PP (TO to) (NP (CD 2.40))) (: ;) (NP (NP (NNP I2)) (: ;) (NP (NP (CD 4) (NNS RCTs)) (: ;) (NP (JJ low‐certainty) (NN evidence)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is to 2.40 ; I2 ; 4 RCTs ; low‐certainty evidence .","phraseText":"to 2.40 ; I2 ; 4 RCTs ; low‐certainty evidence ."}],"linkedContexts":[],"text":"CI 0.90 95 % ."},"76d9c28e3a7e44359918d312bde587bf":{"id":"76d9c28e3a7e44359918d312bde587bf","parseTree":"(ROOT (NP (NP (CD =) (CD 0) (NN %)) (NP (NNP I2)) (. .)))","sentenceIdx":13,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"= 0 % I2 ."},"5c34ccefd92646e5bfe58984e0d071af":{"id":"5c34ccefd92646e5bfe58984e0d071af","parseTree":"(ROOT (S (NP (CD 4) (NNS RCTs)) (VP (VBP are) (NP (CD 5143) (NNS participants))) (. .)))","sentenceIdx":13,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"4 RCTs are 5143 participants ."},"8e958e3acf06474faafa9e7d9de4cc69":{"id":"8e958e3acf06474faafa9e7d9de4cc69","parseTree":"(ROOT (NP (NP (NP (NNP RR) (CD 0.87)) (SBAR (S (VP (VBZ is) (NP (CD 95) (NN %)))))) (NP (NP (NNP CI) (CD 0.72)) (PP (TO to) (NP (CD 1.05)))) (: ;) (NP (NP (NNP I2)) (SBAR (S (VP (SYM =) (NP (CD 60) (NN %)))))) (: ;) (NP (NP (CD 8) (NNS RCTs)) (: ;) (NP (JJ low‐certainty) (NN evidence))) (. .)))","sentenceIdx":13,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"0c59dc2858434e6781c22ac87a92cea4","relation":"ELABORATION"}],"text":"RR 0.87 is 95 % CI 0.72 to 1.05 ; I2 = 60 % ; 8 RCTs ; low‐certainty evidence ."},"0c59dc2858434e6781c22ac87a92cea4":{"id":"0c59dc2858434e6781c22ac87a92cea4","parseTree":"(ROOT (S (NP (CD 8) (NNS RCTs)) (VP (VBP are) (NP (CD 5592) (NNS participants))) (. .)))","sentenceIdx":13,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"8 RCTs are 5592 participants ."},"442c7be25e3f428ebcb27ebf9dd27010":{"id":"442c7be25e3f428ebcb27ebf9dd27010","parseTree":"(ROOT (NP (NP (NP (NNP RR) (CD 0.88)) (SBAR (S (VP (VBZ is) (NP (CD 95) (NN %)))))) (NP (NP (NNP CI) (CD 0.73)) (PP (TO to) (NP (CD 1.06)))) (: ;) (NP (NP (NNP I2)) (SBAR (S (VP (SYM =) (NP (CD 0) (NN %)))))) (: ;) (NP (NP (CD 5) (NNS RCTs)) (: ;) (NP (JJ moderate‐certainty) (NN evidence))) (. .)))","sentenceIdx":13,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"43b86dcb0068453792b4d3ff3c6f2afb","relation":"ELABORATION"}],"text":"RR 0.88 is 95 % CI 0.73 to 1.06 ; I2 = 0 % ; 5 RCTs ; moderate‐certainty evidence ."},"43b86dcb0068453792b4d3ff3c6f2afb":{"id":"43b86dcb0068453792b4d3ff3c6f2afb","parseTree":"(ROOT (S (NP (CD 5) (NNS RCTs)) (VP (VBP are) (NP (CD 4645) (NNS participants))) (. .)))","sentenceIdx":13,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"5 RCTs are 4645 participants ."}}},{"sentenceIdx":14,"originalSentence":"Vitamin D supplementation during pregnancy may help improve maternal and neonatal health outcomes (such as fewer preterm birth and low birthweight babies) and reduce the risk of adverse pregnancy outcomes (such as severe postpartum haemorrhage). ","elementMap":{"c72f67466a544088abdbd70b18efd7db":{"id":"c72f67466a544088abdbd70b18efd7db","parseTree":"(ROOT (S (NP (NP (NNP Vitamin) (NNP D)) (VP (VBN supplementation) (PP (IN during) (NP (NN pregnancy))))) (VP (MD may) (VP (VB help) (VP (VB improve) (NP (NP (ADJP (JJ maternal) (CC and) (JJ neonatal)) (NN health) (NNS outcomes)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (JJR fewer) (NN preterm) (NN birth))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":14,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"c5d0592f28404caaa4a7d7ab36bf38d7","relation":"LIST"},{"targetID":"c4d56f0a5e3c480a9f6b23304f29a31e","relation":"LIST"}],"text":"Vitamin D supplementation during pregnancy may help improve maternal and neonatal health outcomes -LRB- such as fewer preterm birth -RRB- ."},"c5d0592f28404caaa4a7d7ab36bf38d7":{"id":"c5d0592f28404caaa4a7d7ab36bf38d7","parseTree":"(ROOT (S (NP (NP (NNP Vitamin) (NNP D)) (VP (VBN supplementation) (PP (IN during) (NP (NN pregnancy))))) (VP (MD may) (VP (VB help) (VP (VB improve) (NP (NP (ADJP (JJ maternal) (CC and) (JJ neonatal)) (NN health) (NNS outcomes)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (JJ low) (NN birthweight) (NNS babies))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":14,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"c72f67466a544088abdbd70b18efd7db","relation":"LIST"},{"targetID":"c4d56f0a5e3c480a9f6b23304f29a31e","relation":"LIST"}],"text":"Vitamin D supplementation during pregnancy may help improve maternal and neonatal health outcomes -LRB- such as low birthweight babies -RRB- ."},"c4d56f0a5e3c480a9f6b23304f29a31e":{"id":"c4d56f0a5e3c480a9f6b23304f29a31e","parseTree":"(ROOT (S (NP (NP (NNP Vitamin) (NNP D)) (VP (VBN supplementation) (PP (IN during) (NP (NN pregnancy))))) (VP (MD may) (VP (VB help) (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ adverse) (NN pregnancy) (NNS outcomes)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (JJ severe) (NN postpartum) (NN haemorrhage))) (-RRB- -RRB-)))))))) (. .)))","sentenceIdx":14,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"c72f67466a544088abdbd70b18efd7db","relation":"LIST"},{"targetID":"c5d0592f28404caaa4a7d7ab36bf38d7","relation":"LIST"}],"text":"Vitamin D supplementation during pregnancy may help reduce the risk of adverse pregnancy outcomes -LRB- such as severe postpartum haemorrhage -RRB- ."}}},{"sentenceIdx":15,"originalSentence":"Selection criteria: Randomised and quasi‐randomised trials evaluating the effect of supplementation with vitamin D alone or in combination with other micronutrients for women during pregnancy in comparison to placebo or no intervention. ","elementMap":{"909ddb4d09de4797bb9b7525e21206ad":{"id":"909ddb4d09de4797bb9b7525e21206ad","parseTree":"(ROOT (NP (NP (NN Selection) (NNS criteria)) (: :) (NP (NP (NNP Randomised)) (CC and) (NP (NP (JJ quasi‐randomised) (NNS trials)) (VP (VBG evaluating) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN supplementation)) (PP (IN with) (NP (NNP vitamin) (NNP D))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination))))))) (PP (IN with) (NP (NP (JJ other) (NNS micronutrients)) (PP (IN for) (NP (NNS women))))) (PP (IN during) (NP (NP (NN pregnancy)) (PP (IN in) (NP (NN comparison))))) (PP (TO to) (NP (NP (NN placebo)) (CC or) (NP (DT no) (NN intervention))))))) (. .)))","sentenceIdx":15,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"Selection criteria : Randomised and quasi‐randomised trials evaluating the effect of supplementation with vitamin D alone or in combination with other micronutrients for women during pregnancy in comparison to placebo or no intervention ."}}},{"sentenceIdx":16,"originalSentence":"The evidence is very uncertain about the effect of supplementation with vitamin D during pregnancy compared to placebo or no intervention on pre‐eclampsia (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.21 to 1.33; 1 study, 165 women), gestational diabetes (RR 0.53, 95% CI 0.03 to 8.28; 1 study, 165 women), preterm birth (< 37 weeks) (RR 0.76, 95% CI 0.25 to 2.33; 3 studies, 1368 women), nephritic syndrome (RR 0.17, 95% CI 0.01 to 4.06; 1 study, 135 women), or hypercalcaemia (1 study; no cases reported).","elementMap":{"a11b43d0eb5f47cba9f7350d964ac114":{"id":"a11b43d0eb5f47cba9f7350d964ac114","parseTree":"(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (RB very) (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN supplementation)))))) (PP (IN with) (NP (NP (NNP vitamin) (NNP D)) (PP (IN during) (NP (NN pregnancy)))))) (. .)))","sentenceIdx":16,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"09523feddba842c0a4fd75097eb468b8","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"4c84c5a4b0fe48adbb12bfa0c1122e4e","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"43719988b2ac488895be1f7a662f0ee1","relation":"ELABORATION"},{"targetID":"aba7c7b6d3a04da082838ad58909574f","relation":"ELABORATION"},{"targetID":"a8569dbbb2e7409b8e8607b0473a8d2a","relation":"ELABORATION"},{"targetID":"cb4baf03577b4f98bc1fdb26002f0ade","relation":"ELABORATION"}],"text":"The evidence is very uncertain about the effect of supplementation with vitamin D during pregnancy ."},"09523feddba842c0a4fd75097eb468b8":{"id":"09523feddba842c0a4fd75097eb468b8","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (VBN compared) (PP (TO to) (NP (NN placebo))))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"4c84c5a4b0fe48adbb12bfa0c1122e4e","relation":"DISJUNCTION"}],"text":"This was compared to placebo ."},"4c84c5a4b0fe48adbb12bfa0c1122e4e":{"id":"4c84c5a4b0fe48adbb12bfa0c1122e4e","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (VBN compared) (PP (TO to) (NP (NP (DT no) (NN intervention)) (PP (IN on) (NP (NP (NP (NN pre‐eclampsia)) (-LRB- -LRB-) (NP (NP (NN risk) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NNP RR)) (-RRB- -RRB-)) (NP (CD 0.53) (CD 1) (NN study) (, ,) (CD 165) (NNS women))) (-RRB- -RRB-)) (, ,) (NP (NP (JJ gestational) (NN diabetes)) (PRN (-LRB- -LRB-) (NP (NP (NNP RR) (CD 0.53)) (NP (CD 165) (NNS women))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN preterm) (NN birth)) (PRN (-LRB- -LRB-) (NP (QP (CD <) (CD 37)) (NNS weeks)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NNP RR) (CD 0.76)) (NP (CD 1368) (NNS women))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ nephritic) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NP (NNP RR) (CD 0.17)) (NP (CD 135) (NNS women))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN hypercalcaemia)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN study)) (: ;) (NP (DT no) (NNS cases) (JJ reported))) (-RRB- -RRB-))))))))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"09523feddba842c0a4fd75097eb468b8","relation":"DISJUNCTION"}],"text":"This was compared to no intervention on pre‐eclampsia -LRB- risk ratio -LRB- RR -RRB- 0.53 1 study , 165 women -RRB- , gestational diabetes -LRB- RR 0.53 165 women -RRB- , preterm birth -LRB- < 37 weeks -RRB- -LRB- RR 0.76 1368 women -RRB- , nephritic syndrome -LRB- RR 0.17 135 women -RRB- , or hypercalcaemia -LRB- 1 study ; no cases reported -RRB- ."},"43719988b2ac488895be1f7a662f0ee1":{"id":"43719988b2ac488895be1f7a662f0ee1","parseTree":"(ROOT (S (NP (NNP RR) (NNP 0.17)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NP (NNP CI) (CD 0.01)) (PP (TO to) (NP (CD 4.06)))) (: ;) (NP (CD 1) (NN study)))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"RR 0.17 was 95 % CI 0.01 to 4.06 ; 1 study ."},"aba7c7b6d3a04da082838ad58909574f":{"id":"aba7c7b6d3a04da082838ad58909574f","parseTree":"(ROOT (S (NP (NNP RR) (NNP 0.76)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NP (NNP CI) (CD 0.25)) (PP (TO to) (NP (CD 2.33)))) (: ;) (NP (CD 3) (NNS studies)))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"RR 0.76 was 95 % CI 0.25 to 2.33 ; 3 studies ."},"a8569dbbb2e7409b8e8607b0473a8d2a":{"id":"a8569dbbb2e7409b8e8607b0473a8d2a","parseTree":"(ROOT (S (NP (NNP RR) (NNP 0.53)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NP (NNP CI) (CD 0.03)) (PP (TO to) (NP (CD 8.28)))) (: ;) (NP (CD 1) (NN study)))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"RR 0.53 was 95 % CI 0.03 to 8.28 ; 1 study ."},"cb4baf03577b4f98bc1fdb26002f0ade":{"id":"cb4baf03577b4f98bc1fdb26002f0ade","parseTree":"(ROOT (S (NP (NP (NN Risk) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NNP RR)) (-RRB- -RRB-))) (ADVP (RB 0.53)) (VP (VBD was) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (NP (QP (CD 0.21) (TO to) (CD 1.33)))) (. .)))","sentenceIdx":16,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Risk ratio -LRB- RR -RRB- 0.53 was 95 % confidence interval -LRB- CI -RRB- 0.21 to 1.33 ."}}},{"sentenceIdx":17,"originalSentence":"Supplementation with vitamin D during pregnancy may reduce the risk of severe postpartum haemorrhage; however, only one study reported this outcome (RR 0.68, 95% CI 0.51 to 0.91; 1 study, 1134 women; low‐certainty evidence) and may reduce the risk of low birthweight; however, the upper CI suggests that an increase in risk cannot be ruled out (RR 0.69, 95% CI 0.44 to 1.08; 3 studies, 371 infants; low‐certainty evidence). ","elementMap":{"8afc3264792349b692797bd5a0e5593c":{"id":"8afc3264792349b692797bd5a0e5593c","parseTree":"(ROOT (S (NP (NP (NNP Supplementation)) (PP (IN with) (NP (NP (NNP vitamin) (NNP D)) (PP (IN during) (NP (NN pregnancy)))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ severe) (NN postpartum) (NN haemorrhage)))))) (. .)))","sentenceIdx":17,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"54ff3af278a64e2f95f652bab777cfc8","relation":"CONTRAST"},{"targetID":"2ca0ef4f6c9d4c778e1f229d41afa0e6","relation":"CONTRAST"},{"targetID":"dc72db273d6a4060a655f138a1d2fa83","relation":"CONTRAST"}],"text":"Supplementation with vitamin D during pregnancy may reduce the risk of severe postpartum haemorrhage ."},"54ff3af278a64e2f95f652bab777cfc8":{"id":"54ff3af278a64e2f95f652bab777cfc8","parseTree":"(ROOT (S (NP (RB Only) (CD one) (NN study)) (VP (VBD reported) (NP (NP (DT this) (NN outcome)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.68)) (-RRB- -RRB-)))) (. .)))","sentenceIdx":17,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"2ca0ef4f6c9d4c778e1f229d41afa0e6","relation":"LIST"},{"targetID":"9affe92e20ce48c5b1794520af707c59","relation":"ELABORATION"},{"targetID":"8afc3264792349b692797bd5a0e5593c","relation":"CONTRAST"},{"targetID":"dc72db273d6a4060a655f138a1d2fa83","relation":"CONTRAST"}],"text":"Only one study reported this outcome -LRB- RR 0.68 -RRB- ."},"2ca0ef4f6c9d4c778e1f229d41afa0e6":{"id":"2ca0ef4f6c9d4c778e1f229d41afa0e6","parseTree":"(ROOT (S (NP (RB Only) (CD one) (NN study)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ low) (NN birthweight)))))) (. .)))","sentenceIdx":17,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"54ff3af278a64e2f95f652bab777cfc8","relation":"LIST"},{"targetID":"9affe92e20ce48c5b1794520af707c59","relation":"ELABORATION"},{"targetID":"8afc3264792349b692797bd5a0e5593c","relation":"CONTRAST"},{"targetID":"dc72db273d6a4060a655f138a1d2fa83","relation":"CONTRAST"}],"text":"Only one study may reduce the risk of low birthweight ."},"9affe92e20ce48c5b1794520af707c59":{"id":"9affe92e20ce48c5b1794520af707c59","parseTree":"(ROOT (S (NP (NNP RR) (CD 0.68)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NP (NNP CI) (CD 0.51)) (PP (TO to) (NP (CD 0.91)))) (: ;) (NP (NP (CD 1) (NN study)) (: ;) (NP (JJ low‐certainty) (NN evidence))))) (. .)))","sentenceIdx":17,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"8ed6e2ed9cd5421caea318d02474ee5f","relation":"ELABORATION"}],"text":"RR 0.68 was 95 % CI 0.51 to 0.91 ; 1 study ; low‐certainty evidence ."},"8ed6e2ed9cd5421caea318d02474ee5f":{"id":"8ed6e2ed9cd5421caea318d02474ee5f","parseTree":"(ROOT (S (NP (CD 1) (NN study)) (VP (VBD was) (NP (CD 1134) (NNS women))) (. .)))","sentenceIdx":17,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"1 study was 1134 women ."},"dc72db273d6a4060a655f138a1d2fa83":{"id":"dc72db273d6a4060a655f138a1d2fa83","parseTree":"(ROOT (S (NP (DT The) (JJ upper) (NN CI)) (VP (VBZ suggests)) (. .)))","sentenceIdx":17,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"f70ad16cf9534954a8054098b6137c96","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"44898d4cee2f4f31a633e15738763521","relation":"ELABORATION"},{"targetID":"8afc3264792349b692797bd5a0e5593c","relation":"CONTRAST"},{"targetID":"54ff3af278a64e2f95f652bab777cfc8","relation":"CONTRAST"},{"targetID":"2ca0ef4f6c9d4c778e1f229d41afa0e6","relation":"CONTRAST"}],"text":"The upper CI suggests ."},"f70ad16cf9534954a8054098b6137c96":{"id":"f70ad16cf9534954a8054098b6137c96","parseTree":"(ROOT (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NN risk)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN ruled) (ADVP (RB out)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.69)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":17,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"An increase in risk can not be ruled out -LRB- RR 0.69 -RRB- ."},"44898d4cee2f4f31a633e15738763521":{"id":"44898d4cee2f4f31a633e15738763521","parseTree":"(ROOT (S (NP (NNP RR) (CD 0.69)) (VP (VBD was) (NP (CD 95) (NN %)) (NP (NP (NP (NNP CI) (CD 0.44)) (PP (TO to) (NP (CD 1.08)))) (: ;) (NP (NP (CD 3) (NNS studies)) (: ;) (NP (JJ low‐certainty) (NN evidence))))) (. .)))","sentenceIdx":17,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"7a72ecd8348249f9a00e43f8ff5b3735","relation":"ELABORATION"}],"text":"RR 0.69 was 95 % CI 0.44 to 1.08 ; 3 studies ; low‐certainty evidence ."},"7a72ecd8348249f9a00e43f8ff5b3735":{"id":"7a72ecd8348249f9a00e43f8ff5b3735","parseTree":"(ROOT (S (NP (CD 3) (NNS studies)) (VP (VBD were) (NP (CD 371) (NNS infants))) (. .)))","sentenceIdx":17,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"3 studies were 371 infants ."}}},{"sentenceIdx":18,"originalSentence":"The evidence is very uncertain about the effect of supplementation with vitamin D and calcium on preterm birth (RR not estimable; very low‐certainty evidence) or for low birthweight (RR 1.45, 95% CI 0.14 to 14.94; very low‐certainty evidence) compared to women who received placebo or no intervention. ","elementMap":{"8b0ed54b7c454e0392f39c32c1dd2154":{"id":"8b0ed54b7c454e0392f39c32c1dd2154","parseTree":"(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (RB very) (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN supplementation)) (PP (PP (IN with) (NP (NNP vitamin) (NNP D))) (PRN (-LRB- -LRB-) (S (VP (VB RR) (RB not) (VP (VB estimable) (: ;) (NP (RB very) (JJ low‐certainty) (NN evidence))))) (-RRB- -RRB-)) (CC or) (PP (IN for) (NP (NP (NP (JJ low) (NN birthweight)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.45)) (-RRB- -RRB-))) (PP (VBN compared) (PP (TO to) (NP (NNS women))))))))))))) (. .)))","sentenceIdx":18,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"bb095b205b744d2cbf27eb22dafb431b","relation":"LIST"},{"targetID":"aa3ebf1f56a04ee09cb254e42a2d0d25","relation":"IDENTIFYING_DEFINITION"},{"targetID":"146db9569d23461c9aae84cc66465717","relation":"IDENTIFYING_DEFINITION"},{"targetID":"02c9749f43d943149c2881ba571a62b2","relation":"ELABORATION"}],"text":"The evidence is very uncertain about the effect of supplementation with vitamin D -LRB- RR not estimable ; very low‐certainty evidence -RRB- or for low birthweight -LRB- RR 1.45 -RRB- compared to women ."},"bb095b205b744d2cbf27eb22dafb431b":{"id":"bb095b205b744d2cbf27eb22dafb431b","parseTree":"(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (RB very) (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN supplementation)) (PP (PP (IN with) (NP (NP (NN calcium)) (PP (IN on) (NP (NN preterm) (NN birth))))) (PRN (-LRB- -LRB-) (S (VP (VB RR) (RB not) (VP (VB estimable) (: ;) (NP (RB very) (JJ low‐certainty) (NN evidence))))) (-RRB- -RRB-)) (CC or) (PP (IN for) (NP (NP (NP (JJ low) (NN birthweight)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.45)) (-RRB- -RRB-))) (PP (VBN compared) (PP (TO to) (NP (NNS women))))))))))))) (. .)))","sentenceIdx":18,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"8b0ed54b7c454e0392f39c32c1dd2154","relation":"LIST"},{"targetID":"aa3ebf1f56a04ee09cb254e42a2d0d25","relation":"IDENTIFYING_DEFINITION"},{"targetID":"146db9569d23461c9aae84cc66465717","relation":"IDENTIFYING_DEFINITION"},{"targetID":"02c9749f43d943149c2881ba571a62b2","relation":"ELABORATION"}],"text":"The evidence is very uncertain about the effect of supplementation with calcium on preterm birth -LRB- RR not estimable ; very low‐certainty evidence -RRB- or for low birthweight -LRB- RR 1.45 -RRB- compared to women ."},"aa3ebf1f56a04ee09cb254e42a2d0d25":{"id":"aa3ebf1f56a04ee09cb254e42a2d0d25","parseTree":"(ROOT (S (NP (NNP Women)) (VP (VBD received) (NP (NN placebo))) (. .)))","sentenceIdx":18,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"146db9569d23461c9aae84cc66465717","relation":"DISJUNCTION"}],"text":"Women received placebo ."},"146db9569d23461c9aae84cc66465717":{"id":"146db9569d23461c9aae84cc66465717","parseTree":"(ROOT (S (NP (NNP Women)) (VP (VBD received) (NP (DT no) (NN intervention))) (. .)))","sentenceIdx":18,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"aa3ebf1f56a04ee09cb254e42a2d0d25","relation":"DISJUNCTION"}],"text":"Women received no intervention ."},"02c9749f43d943149c2881ba571a62b2":{"id":"02c9749f43d943149c2881ba571a62b2","parseTree":"(ROOT (S (NP (NNP RR) (NNP 1.45)) (VP (VBD was) (NP (ADJP (CD 95) (NN %)) (NNP CI) (NNPS 0.14))) (. .)))","sentenceIdx":18,"contextLayer":1,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (CD 14.94)) (: ;) (NP (ADJP (RB very) (JJ low‐certainty)) (NN evidence))))) (. .)))","phrase":"(ROOT (NP (X (X (TO to)) (NP (CD 14.94))) (: ;) (NP (RB very) (JJ low‐certainty) (NN evidence)) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was to 14.94 ; very low‐certainty evidence .","phraseText":"to 14.94 ; very low‐certainty evidence ."}],"linkedContexts":[],"text":"RR 1.45 was 95 % CI 0.14 ."}}},{"sentenceIdx":19,"originalSentence":"Feeding via a tube misplaced in the trachea can result in severe pneumonia.","elementMap":{"bb583bb96f46420092e847372fc2120e":{"id":"bb583bb96f46420092e847372fc2120e","parseTree":"(ROOT (S (NP (NP (NNP Feeding)) (PP (IN via) (NP (DT a) (NN tube)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ severe) (NN pneumonia))))) (. .)))","sentenceIdx":19,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"1cdb8b011eff4ef9b32ba5547eebaaf9","relation":"IDENTIFYING_DEFINITION"}],"text":"Feeding via a tube can result in severe pneumonia ."},"1cdb8b011eff4ef9b32ba5547eebaaf9":{"id":"1cdb8b011eff4ef9b32ba5547eebaaf9","parseTree":"(ROOT (S (NP (DT A) (NN tube)) (VP (VBZ is) (VP (VBN misplaced) (PP (IN in) (NP (DT the) (NN trachea))))) (. .)))","sentenceIdx":19,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"A tube is misplaced in the trachea ."}}},{"sentenceIdx":20,"originalSentence":"The objective was to assess the diagnostic accuracy of ultrasound alone or in combination with other methods for gastric tube placement confirmation in children and adults. ","elementMap":{"584bda511cd044a3941b810a809b1816":{"id":"584bda511cd044a3941b810a809b1816","parseTree":"(ROOT (S (NP (DT The) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ diagnostic) (NN accuracy)) (PP (IN of) (NP (NNP ultrasound) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS methods)) (PP (IN for) (NP (JJ gastric) (NN tube)))))))) (NN placement) (NN confirmation)))))))) (. .)))","sentenceIdx":20,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NNS children) (CC and) (NNS adults)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN in) (NP (NNS children) (CC and) (NNS adults))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was in children and adults .","phraseText":"in children and adults ."}],"linkedContexts":[],"text":"The objective was to assess the diagnostic accuracy of ultrasound alone or in combination with other methods for gastric tube placement confirmation ."}}},{"sentenceIdx":21,"originalSentence":"Based on limited evidence, ultrasound does not have sufficient accuracy as a single test to confirm gastric tube placement.","elementMap":{"91f775459c5f404ba3ba1797d1eee82b":{"id":"91f775459c5f404ba3ba1797d1eee82b","parseTree":"(ROOT (S (NP (NNP Ultrasound)) (VP (VBZ does) (RB not) (VP (VB have) (NP (NP (JJ sufficient) (NN accuracy)) (PP (IN as) (NP (DT a) (JJ single) (NN test)))))) (. .)))","sentenceIdx":21,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (JJ limited) (NN evidence))))) (. .)))","phrase":"(ROOT (S (VP (VBN based) (PP (IN on) (NP (JJ limited) (NN evidence)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is based on limited evidence .","phraseText":"based on limited evidence ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (S (VP (TO to) (VP (VB confirm) (NP (JJ gastric) (NN tube) (NN placement)))))) (. .)))","phrase":"(ROOT (S (VP (TO to) (VP (VB confirm) (NP (JJ gastric) (NN tube) (NN placement)))) (. .)))","relation":"PURPOSE","timeInformation":null,"text":"This is to confirm gastric tube placement .","phraseText":"to confirm gastric tube placement ."}],"linkedContexts":[],"text":"Ultrasound does not have sufficient accuracy as a single test ."}}},{"sentenceIdx":22,"originalSentence":"Our 2009 Cochrane review found that calcium channel blockers (CCBs) improved graft function and prevented graft loss, while the evidence for other BP‐lowering treatments was limited. ","elementMap":{"fabc14d76fea4409b1dcfb3a8a089e8c":{"id":"fabc14d76fea4409b1dcfb3a8a089e8c","parseTree":"(ROOT (S (NP (PRP$ Our) (CD 2009) (NN Cochrane) (NN review)) (VP (VBD found)) (. .)))","sentenceIdx":22,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"4cd3c92bf83749a494bfb963db3f7e2d","relation":"CONTRAST"},{"targetID":"479279885531437185126232e25ca3c1","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"01e4da47d0064cd9b4e6ebc0b202ab6a","relation":"UNKNOWN_SUBORDINATION"}],"text":"Our 2009 Cochrane review found ."},"4cd3c92bf83749a494bfb963db3f7e2d":{"id":"4cd3c92bf83749a494bfb963db3f7e2d","parseTree":"(ROOT (S (NP (NP (DT The) (NN evidence)) (PP (IN for) (NP (JJ other) (NN BP‐lowering) (NNS treatments)))) (VP (VBD was) (VP (VBN limited))) (. .)))","sentenceIdx":22,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"fabc14d76fea4409b1dcfb3a8a089e8c","relation":"CONTRAST"},{"targetID":"479279885531437185126232e25ca3c1","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"01e4da47d0064cd9b4e6ebc0b202ab6a","relation":"UNKNOWN_SUBORDINATION"}],"text":"The evidence for other BP‐lowering treatments was limited ."},"479279885531437185126232e25ca3c1":{"id":"479279885531437185126232e25ca3c1","parseTree":"(ROOT (S (NP (NP (JJ Calcium) (NN channel) (NNS blockers)) (PRN (-LRB- -LRB-) (NP (NNP CCBs)) (-RRB- -RRB-))) (VP (VBD improved) (NP (NN graft) (NN function))) (. .)))","sentenceIdx":22,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"01e4da47d0064cd9b4e6ebc0b202ab6a","relation":"LIST"}],"text":"Calcium channel blockers -LRB- CCBs -RRB- improved graft function ."},"01e4da47d0064cd9b4e6ebc0b202ab6a":{"id":"01e4da47d0064cd9b4e6ebc0b202ab6a","parseTree":"(ROOT (S (NP (NP (JJ Calcium) (NN channel) (NNS blockers)) (PRN (-LRB- -LRB-) (NP (NNP CCBs)) (-RRB- -RRB-))) (VP (VBD prevented) (NP (NN graft) (NN loss))) (. .)))","sentenceIdx":22,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"479279885531437185126232e25ca3c1","relation":"LIST"}],"text":"Calcium channel blockers -LRB- CCBs -RRB- prevented graft loss ."}}},{"sentenceIdx":23,"originalSentence":"Randomised controlled trials (RCTs) and quasi‐RCTs evaluating any BP‐lowering agent in recipients of a functioning kidney transplant for at least two weeks were eligible","elementMap":{"ed0f659cd7d04ec08ef4efda24b0797c":{"id":"ed0f659cd7d04ec08ef4efda24b0797c","parseTree":"(ROOT (S (NP (NP (JJ Randomised) (JJ controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-))) (VP (VBD were) (ADJP (JJ eligible))) (. .)))","sentenceIdx":23,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"cd28bb70573646df93827b9051a3720a","relation":"LIST"}],"text":"Randomised controlled trials -LRB- RCTs -RRB- were eligible ."},"cd28bb70573646df93827b9051a3720a":{"id":"cd28bb70573646df93827b9051a3720a","parseTree":"(ROOT (S (NP (NP (NNS Quasi‐RCTs)) (VP (VBG evaluating) (NP (DT any) (NNP BP‐lowering) (NN agent)) (PP (IN in) (NP (NP (NNS recipients)) (PP (IN of) (NP (NP (DT a) (VBG functioning) (NN kidney) (NN transplant)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD two)) (NNS weeks))))))))) (VP (VBD were) (ADJP (JJ eligible))) (. .)))","sentenceIdx":23,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"ed0f659cd7d04ec08ef4efda24b0797c","relation":"LIST"}],"text":"Quasi‐RCTs evaluating any BP‐lowering agent in recipients of a functioning kidney transplant for at least two weeks were eligible ."}}},{"sentenceIdx":24,"originalSentence":"Compared to placebo or standard care alone, CCBs probably reduce all‐cause death and graft loss.","elementMap":{"c9fd5d55ef8e499fac0720e2721be113":{"id":"c9fd5d55ef8e499fac0720e2721be113","parseTree":"(ROOT (S (NP (NNS CCBs)) (ADVP (RB probably)) (VP (VB reduce) (NP (JJ all‐cause) (NN death))) (. .)))","sentenceIdx":24,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (JJ standard) (NN care) (RB alone))))) (. .)))","phrase":"(ROOT (S (S (VP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (NN standard))))) (VP (VBP care) (ADVP (RB alone))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is compared to placebo or standard care alone .","phraseText":"compared to placebo or standard care alone ."}],"linkedContexts":[{"targetID":"084ca7358b1e41638b26354568a51724","relation":"LIST"}],"text":"CCBs probably reduce all‐cause death ."},"084ca7358b1e41638b26354568a51724":{"id":"084ca7358b1e41638b26354568a51724","parseTree":"(ROOT (S (NP (NNS CCBs)) (ADVP (RB probably)) (VP (VB reduce) (NP (NN graft) (NN loss))) (. .)))","sentenceIdx":24,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (JJ standard) (NN care) (RB alone))))) (. .)))","phrase":"(ROOT (S (S (VP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (NN standard))))) (VP (VBP care) (ADVP (RB alone))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is compared to placebo or standard care alone .","phraseText":"compared to placebo or standard care alone ."}],"linkedContexts":[{"targetID":"c9fd5d55ef8e499fac0720e2721be113","relation":"LIST"}],"text":"CCBs probably reduce graft loss ."}}},{"sentenceIdx":25,"originalSentence":"The effects of CCBs, ACEi or ARB compared to placebo or standard care alone on cardiovascular outcomes (including fatal or nonfatal myocardial infarction, fatal or nonfatal stroke) or other adverse events were uncertain. ","elementMap":{"f884b1bb460142b2a7bb2f5c1fa90947":{"id":"f884b1bb460142b2a7bb2f5c1fa90947","parseTree":"(ROOT (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP CCBs) (, ,) (NNP ACEi) (CC or) (NNP ARB))) (PP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (NN standard))))) (VP (VBP care) (ADVP (RB alone)) (PP (IN on) (NP (JJ cardiovascular) (NNS outcomes)))) (. .)))","sentenceIdx":25,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"00fff77f3ed149608a9372ce6c56995f","relation":"DISJUNCTION"},{"targetID":"84869493f4fb48ffb25cf2a3eb842603","relation":"ELABORATION"},{"targetID":"9b3d317e56c1493b8a4c6e0b3430e5ea","relation":"ELABORATION"}],"text":"The effects of CCBs , ACEi or ARB compared to placebo or standard care alone on cardiovascular outcomes ."},"00fff77f3ed149608a9372ce6c56995f":{"id":"00fff77f3ed149608a9372ce6c56995f","parseTree":"(ROOT (S (NP (JJ Other) (JJ adverse) (NNS events)) (VP (VBD were) (ADJP (JJ uncertain))) (. .)))","sentenceIdx":25,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"f884b1bb460142b2a7bb2f5c1fa90947","relation":"DISJUNCTION"},{"targetID":"84869493f4fb48ffb25cf2a3eb842603","relation":"ELABORATION"},{"targetID":"9b3d317e56c1493b8a4c6e0b3430e5ea","relation":"ELABORATION"}],"text":"Other adverse events were uncertain ."},"84869493f4fb48ffb25cf2a3eb842603":{"id":"84869493f4fb48ffb25cf2a3eb842603","parseTree":"(ROOT (S (NP (NNP Fatal)) (VP (VBD was) (NP (ADJP (JJ fatal) (CC or) (JJ nonfatal)) (NN stroke))) (. .)))","sentenceIdx":25,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"9b3d317e56c1493b8a4c6e0b3430e5ea","relation":"DISJUNCTION"}],"text":"Fatal was fatal or nonfatal stroke ."},"9b3d317e56c1493b8a4c6e0b3430e5ea":{"id":"9b3d317e56c1493b8a4c6e0b3430e5ea","parseTree":"(ROOT (S (NP (JJ Nonfatal) (JJ myocardial) (NN infarction)) (VP (VBD was) (NP (ADJP (JJ fatal) (CC or) (JJ nonfatal)) (NN stroke))) (. .)))","sentenceIdx":25,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"84869493f4fb48ffb25cf2a3eb842603","relation":"DISJUNCTION"}],"text":"Nonfatal myocardial infarction was fatal or nonfatal stroke ."}}},{"sentenceIdx":26,"originalSentence":"For kidney transplant recipients, the use of CCB therapy to reduce BP probably reduces death and graft loss compared to placebo or standard care alone, while ARB may reduce graft loss","elementMap":{"a31e99d1eed046cd8797482166a4954d":{"id":"a31e99d1eed046cd8797482166a4954d","parseTree":"(ROOT (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP CCB) (NN therapy))) (S (VP (TO to) (VP (VB reduce) (NP (NNP BP)))))) (ADVP (RB probably)) (VP (VBZ reduces) (NP (NN death) (CC and) (NN graft) (NN loss))) (. .)))","sentenceIdx":26,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (IN for) (NP (NN kidney) (NN transplant) (NNS recipients)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN for) (NP (NN kidney) (NN transplant) (NNS recipients))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is for kidney transplant recipients .","phraseText":"for kidney transplant recipients ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (JJ standard) (NN care) (RB alone))))) (. .)))","phrase":"(ROOT (S (S (VP (VBN compared) (PP (TO to) (NP (NN placebo) (CC or) (NN standard))))) (VP (VBP care) (ADVP (RB alone))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was compared to placebo or standard care alone .","phraseText":"compared to placebo or standard care alone ."}],"linkedContexts":[{"targetID":"74ac7497f6ea4bcd8dc07135cfff40d9","relation":"CONTRAST"}],"text":"The use of CCB therapy to reduce BP probably reduces death and graft loss ."},"74ac7497f6ea4bcd8dc07135cfff40d9":{"id":"74ac7497f6ea4bcd8dc07135cfff40d9","parseTree":"(ROOT (S (NP (NNP ARB)) (VP (MD may) (VP (VB reduce) (NP (NN graft) (NN loss)))) (. .)))","sentenceIdx":26,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"a31e99d1eed046cd8797482166a4954d","relation":"CONTRAST"}],"text":"ARB may reduce graft loss ."}}},{"sentenceIdx":27,"originalSentence":"Cell transplantation offers a potential therapeutic approach to the repair and regeneration of damaged vascular and cardiac tissue after acute myocardial infarction (AMI). ","elementMap":{"804d85b41e614512b7c5c446442cbf28":{"id":"804d85b41e614512b7c5c446442cbf28","parseTree":"(ROOT (S (NP (JJ Cell) (NN transplantation)) (VP (VBZ offers) (NP (DT a) (JJ potential) (JJ therapeutic) (NN approach))) (. .)))","sentenceIdx":27,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"4215b23486274ee6b41a8b71c492ab38","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"8851ebb9d06a4017b16bf3ba752508da","relation":"UNKNOWN_SUBORDINATION"}],"text":"Cell transplantation offers a potential therapeutic approach ."},"4215b23486274ee6b41a8b71c492ab38":{"id":"4215b23486274ee6b41a8b71c492ab38","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT the) (NN repair) (CC and) (NN regeneration)) (PP (IN of) (NP (VBN damaged) (NN vascular)))))) (. .)))","sentenceIdx":27,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"8851ebb9d06a4017b16bf3ba752508da","relation":"LIST"}],"text":"This was to the repair and regeneration of damaged vascular ."},"8851ebb9d06a4017b16bf3ba752508da":{"id":"8851ebb9d06a4017b16bf3ba752508da","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (TO to) (NP (NP (DT the) (NN repair) (CC and) (NN regeneration)) (PP (IN of) (NP (JJ cardiac) (NN tissue))))) (PP (IN after) (NP (NP (ADJP (JJ acute) (JJ myocardial)) (NN infarction)) (PRN (-LRB- -LRB-) (NP (NNP AMI)) (-RRB- -RRB-))))) (. .)))","sentenceIdx":27,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"4215b23486274ee6b41a8b71c492ab38","relation":"LIST"}],"text":"This was to the repair and regeneration of cardiac tissue after acute myocardial infarction -LRB- AMI -RRB- ."}}},{"sentenceIdx":28,"originalSentence":"Normal pressure hydrocephalus (NPH) occurs when the brain ventricles expand, causing a triad of gait, cognitive, and urinary impairment.","elementMap":{"5697b01dca4b4f5db5cdad695cac275c":{"id":"5697b01dca4b4f5db5cdad695cac275c","parseTree":"(ROOT (S (NP (NP (JJ Normal) (NN pressure) (NNS hydrocephalus)) (PRN (-LRB- -LRB-) (NP (NNP NPH)) (-RRB- -RRB-))) (VP (VBZ occurs)) (. .)))","sentenceIdx":28,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"4a264017ad734b73abee88725c2eff55","relation":"BACKGROUND"}],"text":"Normal pressure hydrocephalus -LRB- NPH -RRB- occurs ."},"4a264017ad734b73abee88725c2eff55":{"id":"4a264017ad734b73abee88725c2eff55","parseTree":"(ROOT (S (NP (DT The) (NN brain)) (VP (VBZ ventricles) (VP (VB expand) (, ,) (S (VP (VBG causing) (NP (NP (DT a) (NN triad)) (PP (IN of) (NP (NN gait) (, ,) (NN cognitive) (, ,) (CC and) (NN urinary) (NN impairment)))))))) (. .)))","sentenceIdx":28,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"The brain ventricles expand , causing a triad of gait , cognitive , and urinary impairment ."}}},{"sentenceIdx":29,"originalSentence":"It can occur after a clear brain injury such as trauma, but can also occur without a clear cause (termed idiopathic, or iNPH). ","elementMap":{"f5c2ff60a5684b81bbd63a0df66989b9":{"id":"f5c2ff60a5684b81bbd63a0df66989b9","parseTree":"(ROOT (S (NP (PRP It)) (VP (MD can) (VP (VB occur) (PP (IN after) (NP (NP (DT a) (JJ clear) (NN brain) (NN injury)) (PP (JJ such) (IN as) (NP (NN trauma))))))) (. .)))","sentenceIdx":29,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"ff4c1e907cff4607b3aefb6c0da9cf9f","relation":"CONTRAST"}],"text":"It can occur after a clear brain injury such as trauma ."},"ff4c1e907cff4607b3aefb6c0da9cf9f":{"id":"ff4c1e907cff4607b3aefb6c0da9cf9f","parseTree":"(ROOT (S (NP (PRP It)) (VP (MD can) (ADVP (RB also)) (VP (VB occur) (PP (IN without) (NP (NP (DT a) (JJ clear) (NN cause)) (PRN (-LRB- -LRB-) (VP (VBN termed) (ADJP (ADJP (JJ idiopathic)) (, ,) (CC or) (ADJP (JJ iNPH)))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":29,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"f5c2ff60a5684b81bbd63a0df66989b9","relation":"CONTRAST"}],"text":"It can also occur without a clear cause -LRB- termed idiopathic , or iNPH -RRB- ."}}},{"sentenceIdx":30,"originalSentence":"Non‐randomised studies have shown a benefit from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid (CSF)‐shunting in iNPH, but historically there have been limited randomised controlled trial (RCT) data to confirm this. ","elementMap":{"d6eabb896be54147a04661d4b5f38cc5":{"id":"d6eabb896be54147a04661d4b5f38cc5","parseTree":"(ROOT (S (NP (JJ Non‐randomised) (NNS studies)) (VP (VBP have) (VP (VBN shown) (NP (DT a) (NN benefit)))) (. .)))","sentenceIdx":30,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN from) (S (ADVP (RB surgically)) (VP (VBG diverting) (S (NP (NN ventricular)) (ADJP (JJ fluid) (PP (TO to) (NP (NP (DT an) (NN area)) (PP (IN of) (NP (NP (JJR lower) (NN pressure)) (PP (IN by) (NP (NP (JJ cerebrospinal) (NN fluid)) (PRN (-LRB- -LRB-) (NP (NNP CSF)) (-RRB- -RRB-))))))))) (S (VP (VBG shunting) (PP (IN in) (NP (NN iNPH)))))))))) (. .)))","phrase":"(ROOT (SINV (PP (IN from) (ADVP (RB surgically))) (VP (VBZ diverting)) (NP (NP (NN ventricular) (NN fluid)) (PP (TO to) (NP (DT an) (NN area))) (PP (IN of) (NP (NP (JJR lower) (NN pressure)) (PP (IN by) (NP (JJ cerebrospinal) (NN fluid))))) (PRN (-LRB- -LRB-) (NP (NNP CSF)) (-RRB- -RRB-)) (VP (VBG shunting) (PP (IN in) (NP (NN iNPH))))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid -LRB- CSF -RRB- shunting in iNPH .","phraseText":"from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid -LRB- CSF -RRB- shunting in iNPH ."}],"linkedContexts":[{"targetID":"5d3046507e5043ad8c79d3103aa0ca31","relation":"CONTRAST"}],"text":"Non‐randomised studies have shown a benefit ."},"5d3046507e5043ad8c79d3103aa0ca31":{"id":"5d3046507e5043ad8c79d3103aa0ca31","parseTree":"(ROOT (S (NP (NNP Historically)) (ADVP (RB there)) (VP (VBP have) (VP (VBN been) (VP (VBN limited) (NP (ADJP (JJ randomised) (JJ controlled)) (NN trial) (PRN (-LRB- -LRB-) (NP (NNP RCT)) (-RRB- -RRB-)) (NNS data))))) (. .)))","sentenceIdx":30,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (S (VP (TO to) (VP (VB confirm) (NP (DT this)))))) (. .)))","phrase":"(ROOT (S (VP (TO to) (VP (VB confirm) (NP (DT this)))) (. .)))","relation":"PURPOSE","timeInformation":null,"text":"This was to confirm this .","phraseText":"to confirm this ."}],"linkedContexts":[{"targetID":"d6eabb896be54147a04661d4b5f38cc5","relation":"CONTRAST"}],"text":"Historically there have been limited randomised controlled trial -LRB- RCT -RRB- data ."}}},{"sentenceIdx":31,"originalSentence":"CSF‐shunting probably improves gait speed at less than six months post‐surgery .","elementMap":{"4db8b9ea844242c9a6f47f355b584a41":{"id":"4db8b9ea844242c9a6f47f355b584a41","parseTree":"(ROOT (S (NP (NNP CSF‐shunting)) (ADVP (RB probably)) (VP (VBZ improves) (NP (JJ gait) (NN speed))) (. .)))","sentenceIdx":31,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (IN at) (NP (QP (JJR less) (IN than) (CD six)) (NNS months))) (ADVP (RB post‐surgery))) (. .)))","phrase":"(ROOT (S (VP (PP (IN at) (NP (QP (JJR less) (IN than) (CD six)) (NNS months)) (ADVP (RB post‐surgery)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is at less than six months post‐surgery .","phraseText":"at less than six months post‐surgery ."}],"linkedContexts":[],"text":"CSF‐shunting probably improves gait speed ."}}},{"sentenceIdx":32,"originalSentence":"CSF‐shunting may improve qualitative gait function at less than six months post‐surgery by an uncertain amount ","elementMap":{"429998eb20724e5795cca7a6faf9e175":{"id":"429998eb20724e5795cca7a6faf9e175","parseTree":"(ROOT (S (NP (NNP CSF‐shunting)) (VP (MD may) (VP (VB improve) (NP (JJ qualitative) (NN gait) (NN function)))) (. .)))","sentenceIdx":32,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (IN by) (NP (DT an) (JJ uncertain) (NN amount)))) (. .)))","phrase":"(ROOT (FRAG (PP (IN by) (NP (DT an) (JJ uncertain) (NN amount))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is by an uncertain amount .","phraseText":"by an uncertain amount ."},{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBZ is) (PP (IN at) (NP (QP (JJR less) (IN than) (CD six)) (NNS months))) (ADVP (RB post‐surgery))) (. .)))","phrase":"(ROOT (S (VP (PP (IN at) (NP (QP (JJR less) (IN than) (CD six)) (NNS months)) (ADVP (RB post‐surgery)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This is at less than six months post‐surgery .","phraseText":"at less than six months post‐surgery ."}],"linkedContexts":[],"text":"CSF‐shunting may improve qualitative gait function ."}}},{"sentenceIdx":33,"originalSentence":"The evidence is very uncertain about the effect of CSF‐shunting on cognitive function at less than six months post‐CSF‐shunt surgery.","elementMap":{"f978b53e6e234e9897ca6805a45e8e93":{"id":"f978b53e6e234e9897ca6805a45e8e93","parseTree":"(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (RB very) (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN effect)) (PP (IN of) (S (VP (VBG CSF‐shunting) (PP (IN on) (NP (NP (JJ cognitive) (NN function)) (PP (IN at) (NP (ADJP (NP (QP (JJR less) (IN than) (CD six)) (NNS months)) (JJ post‐CSF‐shunt)) (NN surgery)))))))))))) (. .)))","sentenceIdx":33,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"The evidence is very uncertain about the effect of CSF‐shunting on cognitive function at less than six months post‐CSF‐shunt surgery ."}}},{"sentenceIdx":34,"originalSentence":"Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. ","elementMap":{"40f6825179af4f5d903403774a0f4e9d":{"id":"40f6825179af4f5d903403774a0f4e9d","parseTree":"(ROOT (S (NP (NP (NNP Eczema)) (PRN (-LRB- -LRB-) (NP (JJ atopic) (NNS dermatitis)) (-RRB- -RRB-))) (VP (VBZ is) (NP (DT the) (ADJP (RBS most) (JJ burdensome)) (NN skin) (NN condition)) (ADVP (RB worldwide))) (. .)))","sentenceIdx":34,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"7862159e7ffb4a72a6c265499b91fcd6","relation":"LIST"}],"text":"Eczema -LRB- atopic dermatitis -RRB- is the most burdensome skin condition worldwide ."},"7862159e7ffb4a72a6c265499b91fcd6":{"id":"7862159e7ffb4a72a6c265499b91fcd6","parseTree":"(ROOT (S (NP (NP (NNP Eczema)) (PRN (-LRB- -LRB-) (NP (JJ atopic) (NNS dermatitis)) (-RRB- -RRB-))) (VP (MD can) (RB not) (ADVP (RB currently)) (VP (VB be) (VP (VBN prevented) (CC or) (VBN cured)))) (. .)))","sentenceIdx":34,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"40f6825179af4f5d903403774a0f4e9d","relation":"LIST"}],"text":"Eczema -LRB- atopic dermatitis -RRB- can not currently be prevented or cured ."}}},{"sentenceIdx":35,"originalSentence":"The objective was to compare and rank the efficacy and safety of topical anti‐inflammatory treatments for people with eczema using a network meta‐analysis. ","elementMap":{"d24bf8d322574df1a8ee62540e8e210f":{"id":"d24bf8d322574df1a8ee62540e8e210f","parseTree":"(ROOT (S (NP (DT The) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB compare) (CC and) (VB rank) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (JJ topical) (NN anti‐inflammatory) (NNS treatments)) (PP (IN for) (NP (NP (NNS people)) (PP (IN with) (NP (NN eczema)))))))) (S (VP (VBG using) (NP (DT a) (NN network) (NNS meta‐analysis)))))))) (. .)))","sentenceIdx":35,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"The objective was to compare and rank the efficacy and safety of topical anti‐inflammatory treatments for people with eczema using a network meta‐analysis ."}}},{"sentenceIdx":36,"originalSentence":"We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high‐income countries in secondary care settings.","elementMap":{"91168e003d2e4402bfe2962b4be78741":{"id":"91168e003d2e4402bfe2962b4be78741","parseTree":"(ROOT (S (NP (PRP We)) (VP (VBD included) (NP (NP (CD 291) (NNS studies)) (PP (VBG involving) (NP (NP (CD 45,846) (NNS participants)) (PP (IN with) (NP (NP (DT the) (JJ full) (NN spectrum)) (PP (IN of) (NP (NN eczema) (NN severity))))))))) (. .)))","sentenceIdx":36,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"edfc0a7577ad4446a90d1789853191dc","relation":"UNKNOWN_SUBORDINATION"}],"text":"We included 291 studies involving 45,846 participants with the full spectrum of eczema severity ."},"edfc0a7577ad4446a90d1789853191dc":{"id":"edfc0a7577ad4446a90d1789853191dc","parseTree":"(ROOT (S (NP (NP (DT The) (JJ full) (NN spectrum)) (PP (IN of) (NP (NN eczema) (NN severity)))) (VP (VBD was) (ADVP (RB mainly)) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ high‐income) (NNS countries)) (PP (IN in) (NP (JJ secondary) (NN care) (NNS settings))))))) (. .)))","sentenceIdx":36,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"The full spectrum of eczema severity was mainly conducted in high‐income countries in secondary care settings ."}}},{"sentenceIdx":37,"originalSentence":"Treatment duration and trial participation were a median of 21 and 28 days (ranging from 7 days to 5 years), respectively.","elementMap":{"439f66c559bf497f8374e273790dd34f":{"id":"439f66c559bf497f8374e273790dd34f","parseTree":"(ROOT (S (NP (NNP Treatment) (NNP duration)) (VP (VBD were) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (NP (CD 21) (CC and) (CD 28) (NNS days)) (PRN (-LRB- -LRB-) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 7) (NNS days) (TO to) (CD 5)) (NNS years)))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":37,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (ADVP (RB respectively))) (. .)))","phrase":"(ROOT (FRAG (ADVP (RB respectively)) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was respectively .","phraseText":"respectively ."}],"linkedContexts":[{"targetID":"590ecd01b1de4ebc9b2168c53c919917","relation":"LIST"}],"text":"Treatment duration were a median of 21 and 28 days -LRB- ranging from 7 days to 5 years -RRB- ."},"590ecd01b1de4ebc9b2168c53c919917":{"id":"590ecd01b1de4ebc9b2168c53c919917","parseTree":"(ROOT (S (NP (NNP Trial) (NN participation)) (VP (VBD were) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (NP (CD 21) (CC and) (CD 28) (NNS days)) (PRN (-LRB- -LRB-) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 7) (NNS days) (TO to) (CD 5)) (NNS years)))) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":37,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (ADVP (RB respectively))) (. .)))","phrase":"(ROOT (FRAG (ADVP (RB respectively)) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was respectively .","phraseText":"respectively ."}],"linkedContexts":[{"targetID":"439f66c559bf497f8374e273790dd34f","relation":"LIST"}],"text":"Trial participation were a median of 21 and 28 days -LRB- ranging from 7 days to 5 years -RRB- ."}}},{"sentenceIdx":38,"originalSentence":"NMA of 25 trials reporting skin thinning found no evidence for increased skin thinning with short‐term (median 3 weeks, range 1‐16 weeks) use of mild TCS, moderate TCS, potent TCS, or very potent TCS , all with low confidence.","elementMap":{"5210c3d214de455797c85e6934b167a7":{"id":"5210c3d214de455797c85e6934b167a7","parseTree":"(ROOT (S (NP (NP (NNP NMA)) (PP (IN of) (NP (CD 25) (NNS trials)))) (VP (VBD found) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (VBN increased) (NN skin))))) (. .)))","sentenceIdx":38,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"2acd6f4715a948f0ab1bd3c317ab2a02","relation":"IDENTIFYING_DEFINITION"},{"targetID":"e5330e4af7a84843bc6b0073828cf185","relation":"IDENTIFYING_DEFINITION"},{"targetID":"d79a7c21c68e4072893b1802f45a6b60","relation":"ELABORATION"},{"targetID":"2b1c324e45f840a1a54eaddca8251118","relation":"ELABORATION"}],"text":"NMA of 25 trials found no evidence for increased skin ."},"2acd6f4715a948f0ab1bd3c317ab2a02":{"id":"2acd6f4715a948f0ab1bd3c317ab2a02","parseTree":"(ROOT (S (NP (VBN Increased) (NN skin)) (VP (VBD was) (VP (VBG thinning) (PP (IN with) (NP (NP (NP (JJ short‐term) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (NP-TMP (CD 3) (NNS weeks))) (-RRB- -RRB-)) (NN use)) (PP (IN of) (NP (JJ mild) (NNP TCS) (, ,) (JJ moderate) (NNP TCS) (, ,) (JJ potent) (NNP TCS)))) (, ,) (CC or) (NP (ADJP (RB very) (JJ potent)) (NNP TCS)))))) (. .)))","sentenceIdx":38,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Increased skin was thinning with short‐term -LRB- median 3 weeks -RRB- use of mild TCS , moderate TCS , potent TCS , or very potent TCS ."},"e5330e4af7a84843bc6b0073828cf185":{"id":"e5330e4af7a84843bc6b0073828cf185","parseTree":"(ROOT (S (NP (CD 25) (NNS trials)) (VP (VBD were) (VP (VBG reporting) (NP (NN skin) (NNS thinning)))) (. .)))","sentenceIdx":38,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"25 trials were reporting skin thinning ."},"d79a7c21c68e4072893b1802f45a6b60":{"id":"d79a7c21c68e4072893b1802f45a6b60","parseTree":"(ROOT (S (NP (NNP TCS)) (VP (VBZ is) (NP (NP (DT all)) (PP (IN with) (NP (JJ low) (NN confidence))))) (. .)))","sentenceIdx":38,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"TCS is all with low confidence ."},"2b1c324e45f840a1a54eaddca8251118":{"id":"2b1c324e45f840a1a54eaddca8251118","parseTree":"(ROOT (S (NP (JJ Median) (CD 3) (NNS weeks)) (VP (VBP are) (NP (NN range)) (NP-TMP (CD 1‐16) (NNS weeks))) (. .)))","sentenceIdx":38,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Median 3 weeks are range 1‐16 weeks ."}}},{"sentenceIdx":39,"originalSentence":"The prevalence of tobacco use among people living with HIV (PLWH) is up to four times higher than in the general population.","elementMap":{"ac9cb4e6ba034dddb955d4183527567f":{"id":"ac9cb4e6ba034dddb955d4183527567f","parseTree":"(ROOT (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NP (NN tobacco) (NN use)) (PP (IN among) (NP (NNS people)))))) (VP (VBZ is) (ADJP (ADJP (NP (QP (IN up) (TO to) (CD four)) (NNS times)) (JJR higher)) (PP (IN than) (PP (IN in) (NP (DT the) (JJ general) (NN population)))))) (. .)))","sentenceIdx":39,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"a439084b50674de28667a36e7dc92f4e","relation":"IDENTIFYING_DEFINITION"}],"text":"The prevalence of tobacco use among people is up to four times higher than in the general population ."},"a439084b50674de28667a36e7dc92f4e":{"id":"a439084b50674de28667a36e7dc92f4e","parseTree":"(ROOT (S (NP (NNS People)) (VP (VBP are) (VP (VBG living) (PP (IN with) (NP (NP (NN HIV)) (PRN (-LRB- -LRB-) (NP (NNP PLWH)) (-RRB- -RRB-)))))) (. .)))","sentenceIdx":39,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"People are living with HIV -LRB- PLWH -RRB- ."}}},{"sentenceIdx":40,"originalSentence":"The objective was to assess the benefits, harms and tolerability of interventions for tobacco use cessation among people living with HIV. ","elementMap":{"cd137cd4bbc04651a1729330582a4ad1":{"id":"cd137cd4bbc04651a1729330582a4ad1","parseTree":"(ROOT (S (NP (DT The) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS benefits) (, ,) (NNS harms) (CC and) (NNS tolerability)) (PP (IN of) (NP (NP (NNS interventions)) (PP (IN for) (NP (NN tobacco) (NN use) (NN cessation)))))))))) (. .)))","sentenceIdx":40,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"b9d16011d56b45ab831a770f1557a3cc","relation":"UNKNOWN_SUBORDINATION"}],"text":"The objective was to assess the benefits , harms and tolerability of interventions for tobacco use cessation ."},"b9d16011d56b45ab831a770f1557a3cc":{"id":"b9d16011d56b45ab831a770f1557a3cc","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN among) (NP (NNS people)))) (. .)))","sentenceIdx":40,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"a2af2de554df47d985b99bc2f29e16d6","relation":"IDENTIFYING_DEFINITION"}],"text":"This was among people ."},"a2af2de554df47d985b99bc2f29e16d6":{"id":"a2af2de554df47d985b99bc2f29e16d6","parseTree":"(ROOT (S (NP (NNS People)) (VP (VBD were) (VP (VBG living) (PP (IN with) (NP (NNP HIV))))) (. .)))","sentenceIdx":40,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"People were living with HIV ."}}},{"sentenceIdx":41,"originalSentence":"We included randomised controlled trials (RCTs) of individual‐/group‐level behavioural or pharmacological interventions, or both, for tobacco use cessation, delivered directly to PLWH aged 18 years and over, who use tobacco.","elementMap":{"c587b8b629044170a2a0008b24e1d1bf":{"id":"c587b8b629044170a2a0008b24e1d1bf","parseTree":"(ROOT (S (NP (PRP We)) (VP (VBD included) (NP (NP (NP (JJ randomised) (JJ controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNP RCTs)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ individual) (NNP /) (NN group‐level) (NN behavioural) (CC or) (NN pharmacological) (NNS interventions))) (, ,) (CC or) (NP (DT both)))) (. .)))","sentenceIdx":41,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (NN tobacco) (NN use) (NN cessation)))) (. .)))","phrase":"(ROOT (S (IN for) (NP (NN tobacco)) (VP (VBP use) (NP (NN cessation))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was for tobacco use cessation .","phraseText":"for tobacco use cessation ."}],"linkedContexts":[{"targetID":"57eec73a84054cbe826382d3b7160972","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"ebfb154bade6495eadbfeab5fbb6821f","relation":"DESCRIBING_DEFINITION"}],"text":"We included randomised controlled trials -LRB- RCTs -RRB- of individual / group‐level behavioural or pharmacological interventions , or both ."},"57eec73a84054cbe826382d3b7160972":{"id":"57eec73a84054cbe826382d3b7160972","parseTree":"(ROOT (S (NP (NNP Tobacco) (NN use) (NN cessation)) (VP (VBD was) (VP (VBN delivered) (ADVP (RB directly)) (S (VP (TO to) (VP (VB PLWH) (UCP (VP (VBN aged) (NP-TMP (CD 18) (NNS years))) (CC and) (ADJP (IN over)))))))) (. .)))","sentenceIdx":41,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Tobacco use cessation was delivered directly to PLWH aged 18 years and over ."},"ebfb154bade6495eadbfeab5fbb6821f":{"id":"ebfb154bade6495eadbfeab5fbb6821f","parseTree":"(ROOT (S (NP (DT Both)) (VP (VBD delivered) (ADVP (RB directly)) (S (VP (TO to) (VP (VB PLWH) (UCP (VP (VBN aged) (NP-TMP (CD 18) (NNS years))) (CC and) (PP (IN over) (NP (NN use) (NN tobacco)))))))) (. .)))","sentenceIdx":41,"contextLayer":1,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (NN tobacco) (NN use) (NN cessation)))) (. .)))","phrase":"(ROOT (S (IN for) (NP (NN tobacco)) (VP (VBP use) (NP (NN cessation))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was for tobacco use cessation .","phraseText":"for tobacco use cessation ."}],"linkedContexts":[],"text":"Both delivered directly to PLWH aged 18 years and over use tobacco ."}}},{"sentenceIdx":42,"originalSentence":"We also included RCTs, quasi‐RCTs, other non‐randomised controlled studies (e.g. controlled before and after studies), and interrupted time series studies of system‐change interventions for tobacco use cessation among PLWH. ","elementMap":{"4446218e741f4546a3ca6168a9b398e0":{"id":"4446218e741f4546a3ca6168a9b398e0","parseTree":"(ROOT (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD included) (NP (NNS RCTs))) (. .)))","sentenceIdx":42,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (NP (NN tobacco) (NN use) (NN cessation)) (PP (IN among) (NP (NNP PLWH)))))) (. .)))","phrase":"(ROOT (S (IN for) (NP (NN tobacco)) (VP (VBP use) (NP (NN cessation)) (PP (IN among) (NP (NNP PLWH)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was for tobacco use cessation among PLWH .","phraseText":"for tobacco use cessation among PLWH ."}],"linkedContexts":[{"targetID":"b5ccebaf2a1b42888169a3ca039dbfeb","relation":"LIST"},{"targetID":"63838d8fa3f74615bbce8e0797ccf79a","relation":"ELABORATION"}],"text":"We also included RCTs ."},"b5ccebaf2a1b42888169a3ca039dbfeb":{"id":"b5ccebaf2a1b42888169a3ca039dbfeb","parseTree":"(ROOT (S (NP (PRP We)) (ADVP (RB also)) (VP (VBN interrupted) (NP (NP (NN time) (NN series) (NNS studies)) (PP (IN of) (NP (JJ system‐change) (NNS interventions))))) (. .)))","sentenceIdx":42,"contextLayer":0,"simpleContexts":[{"parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN for) (NP (NP (NN tobacco) (NN use) (NN cessation)) (PP (IN among) (NP (NNP PLWH)))))) (. .)))","phrase":"(ROOT (S (IN for) (NP (NN tobacco)) (VP (VBP use) (NP (NN cessation)) (PP (IN among) (NP (NNP PLWH)))) (. .)))","relation":"UNKNOWN_SUBORDINATION","timeInformation":null,"text":"This was for tobacco use cessation among PLWH .","phraseText":"for tobacco use cessation among PLWH ."}],"linkedContexts":[{"targetID":"4446218e741f4546a3ca6168a9b398e0","relation":"LIST"},{"targetID":"63838d8fa3f74615bbce8e0797ccf79a","relation":"ELABORATION"}],"text":"We also interrupted time series studies of system‐change interventions ."},"63838d8fa3f74615bbce8e0797ccf79a":{"id":"63838d8fa3f74615bbce8e0797ccf79a","parseTree":"(ROOT (S (NP (NNS RCTs)) (VP (VBD was) (NP (NP (NNS quasi‐rcts)) (PRN (-LRB- -LRB-) (NP (NP (NNP e.g.)) (VP (VBN controlled) (PP (IN before) (CC and) (IN after) (NP (NNS studies))))) (-RRB- -RRB-)))) (. .)))","sentenceIdx":42,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"0c1c0bc74c944a0393608b9d573ec9d1","relation":"ELABORATION"}],"text":"RCTs was quasi‐rcts -LRB- e.g. controlled before and after studies -RRB- ."},"0c1c0bc74c944a0393608b9d573ec9d1":{"id":"0c1c0bc74c944a0393608b9d573ec9d1","parseTree":"(ROOT (S (NP (NNS Quasi‐rcts)) (VP (VBD were) (NP (JJ other) (JJ non‐randomised) (JJ controlled) (NNS studies))) (. .)))","sentenceIdx":42,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"Quasi‐rcts were other non‐randomised controlled studies ."}}},{"sentenceIdx":43,"originalSentence":"Low‐certainty evidence did not demonstrate a clear benefit for tobacco use cessation rates in PLWH randomised to receive behavioural support compared with brief advice or no intervention.","elementMap":{"00d00b944da845d59acf6e6101fc3dd8":{"id":"00d00b944da845d59acf6e6101fc3dd8","parseTree":"(ROOT (S (NP (JJ Low‐certainty) (NN evidence)) (VP (VBD did) (RB not) (VP (VB demonstrate) (NP (NP (DT a) (JJ clear) (NN benefit)) (PP (IN for) (NP (NN tobacco) (NN use) (NN cessation) (NNS rates)))))) (. .)))","sentenceIdx":43,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"c66a5860f5ba445e9bf8891d2f103067","relation":"UNKNOWN_SUBORDINATION"}],"text":"Low‐certainty evidence did not demonstrate a clear benefit for tobacco use cessation rates ."},"c66a5860f5ba445e9bf8891d2f103067":{"id":"c66a5860f5ba445e9bf8891d2f103067","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NNP PLWH)))) (. .)))","sentenceIdx":43,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"ff4c662645264bceab13cdb446470f3f","relation":"IDENTIFYING_DEFINITION"}],"text":"This was in PLWH ."},"ff4c662645264bceab13cdb446470f3f":{"id":"ff4c662645264bceab13cdb446470f3f","parseTree":"(ROOT (S (NP (NNP PLWH)) (VP (VBD was) (VP (VBN randomised) (S (VP (TO to) (VP (VB receive) (NP (JJ behavioural) (NN support))))))) (. .)))","sentenceIdx":43,"contextLayer":2,"simpleContexts":[],"linkedContexts":[{"targetID":"aeda66911c554d7182dd5f957de065ee","relation":"UNKNOWN_SUBORDINATION"},{"targetID":"6125bcd0b6ce4ae4aeecebd5e3d13dd6","relation":"UNKNOWN_SUBORDINATION"}],"text":"PLWH was randomised to receive behavioural support ."},"aeda66911c554d7182dd5f957de065ee":{"id":"aeda66911c554d7182dd5f957de065ee","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (VP (VBN compared) (PP (IN with) (NP (JJ brief) (NN advice))))) (. .)))","sentenceIdx":43,"contextLayer":3,"simpleContexts":[],"linkedContexts":[{"targetID":"6125bcd0b6ce4ae4aeecebd5e3d13dd6","relation":"DISJUNCTION"}],"text":"This was compared with brief advice ."},"6125bcd0b6ce4ae4aeecebd5e3d13dd6":{"id":"6125bcd0b6ce4ae4aeecebd5e3d13dd6","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (VP (VBN compared) (PP (IN with) (NP (DT no) (NN intervention))))) (. .)))","sentenceIdx":43,"contextLayer":3,"simpleContexts":[],"linkedContexts":[{"targetID":"aeda66911c554d7182dd5f957de065ee","relation":"DISJUNCTION"}],"text":"This was compared with no intervention ."}}},{"sentenceIdx":44,"originalSentence":"Moderate‐certainty evidence suggested that varenicline may help more PLWH to quit smoking than placebo with no evidence of heterogeneity.","elementMap":{"54f0d55538df4c31a7b15a19d3465bd7":{"id":"54f0d55538df4c31a7b15a19d3465bd7","parseTree":"(ROOT (S (NP (JJ Moderate‐certainty) (NN evidence)) (VP (VBD suggested)) (. .)))","sentenceIdx":44,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"a554c52f07c645afa1f8750a8b6ab3bb","relation":"UNKNOWN_SUBORDINATION"}],"text":"Moderate‐certainty evidence suggested ."},"a554c52f07c645afa1f8750a8b6ab3bb":{"id":"a554c52f07c645afa1f8750a8b6ab3bb","parseTree":"(ROOT (S (NP (NNP Varenicline)) (VP (MD may) (VP (VB help) (NP (JJR more) (NNS PLWH) (S (VP (TO to) (VP (VB quit) (NP (NN smoking)) (PP (IN than) (NP (NN placebo))) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN heterogeneity))))))))))) (. .)))","sentenceIdx":44,"contextLayer":1,"simpleContexts":[],"linkedContexts":[],"text":"Varenicline may help more PLWH to quit smoking than placebo with no evidence of heterogeneity ."}}},{"sentenceIdx":45,"originalSentence":"Low‐certainty evidence did not detect a difference between varenicline and placebo in the proportion of participants experiencing SAEs.","elementMap":{"81b917f5839b49debb946780b7735eb5":{"id":"81b917f5839b49debb946780b7735eb5","parseTree":"(ROOT (S (NP (JJ Low‐certainty) (NN evidence)) (VP (VBD did) (RB not) (VP (VB detect) (NP (NP (DT a) (NN difference)) (PP (IN between) (NP (NN varenicline) (CC and) (NN placebo)))))) (. .)))","sentenceIdx":45,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"ac433c6aa7a54544a54d9e8104fd05c2","relation":"UNKNOWN_SUBORDINATION"}],"text":"Low‐certainty evidence did not detect a difference between varenicline and placebo ."},"ac433c6aa7a54544a54d9e8104fd05c2":{"id":"ac433c6aa7a54544a54d9e8104fd05c2","parseTree":"(ROOT (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NNS participants)))))) (. .)))","sentenceIdx":45,"contextLayer":1,"simpleContexts":[],"linkedContexts":[{"targetID":"41f72dbdde654effa412932ad9001dc2","relation":"IDENTIFYING_DEFINITION"}],"text":"This was in the proportion of participants ."},"41f72dbdde654effa412932ad9001dc2":{"id":"41f72dbdde654effa412932ad9001dc2","parseTree":"(ROOT (S (NP (NNS Participants)) (VP (VBD were) (VP (VBG experiencing) (NP (NNS SAEs)))) (. .)))","sentenceIdx":45,"contextLayer":2,"simpleContexts":[],"linkedContexts":[],"text":"Participants were experiencing SAEs ."}}},{"sentenceIdx":46,"originalSentence":"No studies assessed SAEs for the following: behavioural support plus NRT versus brief advice; varenicline versus NRT and cytisine versus NRT. ","elementMap":{"958918f752ad48aca9434eb0604fe0e6":{"id":"958918f752ad48aca9434eb0604fe0e6","parseTree":"(ROOT (S (NP (DT No) (NNS studies)) (VP (VBD assessed) (NP (NP (NNP SAEs)) (PP (IN for) (NP (DT the) (NN following))))) (. .)))","sentenceIdx":46,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"8eb4a421642241738bbc799a0dc9e70e","relation":"LIST"},{"targetID":"b7125a57a75946a1b9064b00b1d0301b","relation":"LIST"},{"targetID":"219d44bb2783411988f9cd8ea8a87d08","relation":"LIST"}],"text":"No studies assessed SAEs for the following ."},"8eb4a421642241738bbc799a0dc9e70e":{"id":"8eb4a421642241738bbc799a0dc9e70e","parseTree":"(ROOT (S (NP (DT No) (NNS studies)) (VP (VBD assessed) (NP (JJ behavioural) (NN support) (NN plus)) (NP (NP (NNP NRT)) (PP (IN versus) (NP (JJ brief) (NN advice))))) (. .)))","sentenceIdx":46,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"b7125a57a75946a1b9064b00b1d0301b","relation":"LIST"},{"targetID":"219d44bb2783411988f9cd8ea8a87d08","relation":"LIST"},{"targetID":"958918f752ad48aca9434eb0604fe0e6","relation":"LIST"}],"text":"No studies assessed behavioural support plus NRT versus brief advice ."},"b7125a57a75946a1b9064b00b1d0301b":{"id":"b7125a57a75946a1b9064b00b1d0301b","parseTree":"(ROOT (S (NP (DT No) (NNS studies)) (VP (VBD assessed) (NP (NP (NN varenicline)) (PP (IN versus) (NP (NNP NRT))))) (. .)))","sentenceIdx":46,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"219d44bb2783411988f9cd8ea8a87d08","relation":"LIST"},{"targetID":"958918f752ad48aca9434eb0604fe0e6","relation":"LIST"},{"targetID":"8eb4a421642241738bbc799a0dc9e70e","relation":"LIST"}],"text":"No studies assessed varenicline versus NRT ."},"219d44bb2783411988f9cd8ea8a87d08":{"id":"219d44bb2783411988f9cd8ea8a87d08","parseTree":"(ROOT (S (NP (DT No) (NNS studies)) (VP (VBD assessed) (NP (NP (NN cytisine)) (PP (IN versus) (NP (NNP NRT))))) (. .)))","sentenceIdx":46,"contextLayer":0,"simpleContexts":[],"linkedContexts":[{"targetID":"958918f752ad48aca9434eb0604fe0e6","relation":"LIST"},{"targetID":"8eb4a421642241738bbc799a0dc9e70e","relation":"LIST"},{"targetID":"b7125a57a75946a1b9064b00b1d0301b","relation":"LIST"}],"text":"No studies assessed cytisine versus NRT ."}}},{"sentenceIdx":47,"originalSentence":"Repetitive transcranial magnetic stimulation (rTMS) is a non‐invasive therapy involving induction of electrical currents in cortical brain tissue.","elementMap":{"394b107ec75e404fb6aabfb6f9139768":{"id":"394b107ec75e404fb6aabfb6f9139768","parseTree":"(ROOT (S (NP (NP (JJ Repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNS rTMS)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ non‐invasive) (NN therapy)) (PP (VBG involving) (NP (NP (NN induction)) (PP (IN of) (NP (NP (JJ electrical) (NNS currents)) (PP (IN in) (NP (JJ cortical) (NN brain) (NN tissue))))))))) (. .)))","sentenceIdx":47,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"Repetitive transcranial magnetic stimulation -LRB- rTMS -RRB- is a non‐invasive therapy involving induction of electrical currents in cortical brain tissue ."}}},{"sentenceIdx":48,"originalSentence":"Current pharmacological and psychotherapeutic treatments for PTSD are associated with inadequate symptom improvement and high dropout rates. ","elementMap":{"8458ab4c7d084cfebcf270a52bfab8e7":{"id":"8458ab4c7d084cfebcf270a52bfab8e7","parseTree":"(ROOT (S (NP (NP (JJ Current) (ADJP (JJ pharmacological) (CC and) (JJ psychotherapeutic)) (NNS treatments)) (PP (IN for) (NP (NNP PTSD)))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (JJ inadequate) (NN symptom) (NN improvement) (CC and) (JJ high) (NN dropout) (NNS rates))))) (. .)))","sentenceIdx":48,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"Current pharmacological and psychotherapeutic treatments for PTSD are associated with inadequate symptom improvement and high dropout rates ."}}},{"sentenceIdx":49,"originalSentence":"The evidence is very uncertain about the effect of active rTMS on serious adverse events.","elementMap":{"3399d5ceb4aa46e292caee340cec94cb":{"id":"3399d5ceb4aa46e292caee340cec94cb","parseTree":"(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (RB very) (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ active) (NNS rTMS)) (PP (IN on) (NP (JJ serious) (JJ adverse) (NNS events))))))))) (. .)))","sentenceIdx":49,"contextLayer":0,"simpleContexts":[],"linkedContexts":[],"text":"The evidence is very uncertain about the effect of active rTMS on serious adverse events ."}}}]}